Document:

<PAGE>

                                                                   EXHIBIT 10.23

                             BMIPP Supply Agreement

     THIS AGREEMENT made in duplicate as of this 12th day of January, 2006.

BETWEEN:

           MDS NORDION, a division of MDS (Canada) Inc.
           having a place of business at
           447 March Road
           Ottawa, Ontario, Canada

           ("Nordion")

AND:

           MOLECULAR INSIGHT
           PHARMACEUTICALS, INC.
           having a place of business at
           160 Second Street
           Cambridge Massachusetts, 02142 USA

           ("Molecular Insight Pharmaceuticals")

WHEREAS:

I.   Molecular Insight Pharmaceuticals is the owner or licensee of a certain
     compound known as BMIPP (as defined), a heart diagnostic imaging agent;

II.  Nordion has expertise in the production of radiochemicals, in the
     development of radiopharmaceuticals, processes, and in the radiolabelling
     of compounds;

III. Nordion has expertise in designing and overseeing the construction of
     facilities for the radiolabelling of compounds;

IV.  Nordion and Molecular Insight Pharmaceuticals entered into an Agreement as
     of the 16th day of June, 2004, as amended, for the purpose of undertaking a
     development program to establish a process permitting Molecular Insight
     Pharmaceutical's precursor (cold BMIPP) to be labeled with I-123 to form a
     radiopharmaceutical (the "Development Agreement");

V.   Molecular Insight Pharmaceuticals desires that Nordion establish a Facility
     at its site in Vancouver, British Columbia, to accommodate growth and
     expansion of the process developed under the Development Agreement

<PAGE>

                                        2

     for the production and supply of BMIPP to Molecular Insight Pharmaceuticals
     for Clinical Trials and Commercial Phase supply.

VI.  Molecular Insight Pharmaceuticals desires that upon completion of the
     Facility established under this Agreement that Nordion transition the
     manufacture of BMIPP from the existing facility to the new Facility
     established under this Agreement.

NOW THEREFORE in consideration of the mutual covenants and agreements herein
contained, and subject to the terms and conditions hereinafter set out, the
parties hereto agree as follows:

                             ARTICLE 1 - DEFINITIONS

For the purposes of this Agreement:

1.1  "Affiliate" shall mean an entity or person which controls, is controlled by
     or is under common control with either party. For purposes of this section
     1.1 control shall mean (a) in the case of corporate entities, the direct or
     indirect ownership of more than one-half of the stock or participating
     shares entitled to vote for the election of directors, and (b) in the case
     of a partnership, the power to direct the management and policies of such
     partnership.

1.2  "Batch" shall mean a production batch of BMIPP manufactured under this
     Agreement and shall be of the size set forth on Schedule D attached hereto.

1.3  "BMIPP" shall mean I-123 labeled beta-methyl-iodo-phenyl-pentadecanoic acid
     in diagnostic dosage form for use in cardiac imaging (and also known as
     iodofiltic acid I-123).

1.4  "Clinical Trials" shall mean Phase III human trials for clinical
     development of BMIPP for the purpose of seeking pharmaceutical approval in
     the United States.

1.5  "Commercial Phase" shall mean the period of supply of BMIPP commencing
     after NDA regulatory approval has been received in the United States from
     the FDA by Molecular Insight Pharmaceuticals.

1.6  "Current Good Manufacturing Practices" or "cGMP(s)" shall mean the good
     manufacturing practices required by the FDA and as set forth in the FD&C or
     FDA rules and regulations for the manufacturing, testing and quality
     control of pharmaceutical materials as applied to compounds, which
     practices are current on the Effective Date of this Agreement and may be
     supplemented, amended or modified from time to time.

<PAGE>

                                        3

1.7  "Effective Date" shall mean the date first above written.

1.8  "Excipients" shall mean the compounds specified on Schedule G.

1.9  "FDA" shall mean the United States Food and Drug Administration.

1.10 "FD&C" shall mean the United States Federal Food, Drug and Cosmetic Act, as
     amended.

1.11 "Facility" shall mean a new facility to be established by Nordion at its
     manufacturing site in Vancouver, British Columbia as described in Schedule
     A and pursuant to cGMPs, to be used for the production of BMIPP for
     Clinical Trial and Commercial Phase supply.

1.12 "Facility Milestone(s)" shall mean the milestones relating to the
     establishment of the Facility as described in Schedule A.

1.13 "Facility Program" shall mean the program by which Nordion shall establish
     the Facility in accordance with the Facility Milestones as described in
     Schedule A.

1.14 "IND" shall mean an Investigational New Drug Application as defined by the
     rules and regulations promulgated under the FD&C and U.S. Public Health
     Service Act and any supplements, modifications or amendments thereunder.

1.15 "Isotope" or "I-123" shall mean Iodine 123.

1.16 "Master Validation Plan" shall mean the program mutually agreed to by the
     parties by which documented evidence provides assurance that the Process
     will consistently produce BMIPP that meets Specifications.

1.17 "Molecular Insight Pharmaceuticals Background Technology" shall mean
     technology conceived, created, developed or reduced to practice by
     Molecular Insight Pharmaceuticals prior to or during the Term of this
     Agreement or independently of this Agreement, including, without
     limitation, patents, know-how, techniques, methods, processes, drawings,
     schematics, procedures, protocols, parameters, engineering details,
     functional descriptions, data and database content, technical or scientific
     information, manuals and trade secrets, which Molecular Insight
     Pharmaceuticals owns, uses, conceives, creates, develops, reduces to
     practice or provides in performing under this Agreement, or which is
     licensed to Molecular Insight Pharmaceuticals and which is in existence in
     the form of a writing, prototype or can otherwise be demonstrated to be

<PAGE>

                                        4

     the property of Molecular Insight Pharmaceuticals, or to which Molecular
     Insight Pharmaceuticals has the rights.

1.18 "Nordion Background Technology" shall mean technology, conceived, created,
     developed or reduced to practice by Nordion prior to or during the Term of
     this Agreement or independently of this Agreement, including, without
     limitation, patents, know-how, techniques, methods, processes, drawings,
     schematics, procedures, protocols, parameters, engineering details,
     functional descriptions, data and database content, technical or scientific
     information, manuals and trade secrets, which Nordion owns, uses,
     conceives, creates, develops, reduces to practice or provides in performing
     under this Agreement, or which is licensed to Nordion and which is in
     existence in the form of a writing, prototype or can otherwise be
     demonstrated to be the property of Nordion or to which Nordion has the
     rights.

1.19 "NDA" shall mean a new drug application as defined in the rules and
     regulations promulgated under the FD&C and U.S. Public Health Service Act,
     as supplemented, modified or amended from time to time.

1.20 "Precursor" shall mean b-methyl-p-iodophenyl-pentadecanoic acid specified
     in Schedule G and produced pursuant to cGMPs.

1.21 "Process" shall mean the method of formulation, dispensing and testing of
     the BMIPP developed pursuant to the Development Agreement and in compliance
     with cGMPs, which shall be adjusted to accommodate an increase in
     production capability for Clinical Trial and Commercial Phase supply.

1.22 "Quality Agreement" shall mean the agreement set out in Schedule "F".

1.23 "Reference Standards" shall mean the cGMP compliant compounds as specified
     in Schedule G.

1.24 "Specification(s)" shall mean those final specifications for BMIPP as set
     out in Schedule B, as amended by mutual agreement of the parties from time
     to time.

1.25 "Term" shall mean the Initial Term and each Renewal Term as defined in
     section 14.1

The following Schedules attached to this Agreement are hereby incorporated by
reference:

SCHEDULE A: Description of Facility Program, Facility Milestones, Facility
            Schedule

<PAGE>

                                        5

SCHEDULE B: BMIPP Specifications

SCHEDULE C: Facility Construction Fees

SCHEDULE D: Price of Batches for Clinical Trial Supply

SCHEDULE E: Indicative Pricing of BMIPP for Commercial Phase Supply

SCHEDULE F: Quality Agreement

SCHEDULE G: Specifications for Precursor, Reference Standards, and Excipients

                               ARTICLE 2 - PURPOSE

2.1  SCOPE AND OBJECT

     The scope and object of this Agreement is to establish a new facility at
     Nordion's manufacturing site in Vancouver, British Columbia to implement
     the Process for the production and supply of BMIPP for Clinical Trials and
     Commercial Phase supply in accordance with the responsibilities and
     obligations attributed to each of the parties as set out in this Agreement,
     which represents an increase in production and supply from that set forth
     in the Development Agreement.

                          ARTICLE 3 - FACILITY PROGRAM

3.1  FACILITY CONSTRUCTION

     In consideration of Nordion establishing the Facility, Molecular Insight
     Pharmaceuticals will pay to Nordion the fees as set out in Schedule C,
     provided that the respective milestone(s) for establishing the Facility as
     set forth on Schedule A attached hereto are successfully met by Nordion.

     Nordion shall establish the Facility in accordance with its obligations
     described and attributed in Schedule A, it being understood that some
     activities may be reasonably delayed to the extent that such activity is
     premised on the work or provision of data, information or technology by
     Molecular Insight Pharmaceuticals. It is understood and acknowledged that
     due to the nature of the activities to be carried out during the
     establishment of the Facility, the time for completion and sequence for
     carrying out the activities as set out in Schedule A shall serve as a
     guide. Each party shall use their commercially reasonable best efforts in
     order to carry out, in a timely manner, their respective obligations and
     responsibilities set out in Schedule A.

<PAGE>

                                        6

     If either party, acting in good faith, materially fails to satisfy any
     Facility Milestone or is unable to meet such milestone in accordance with
     the timing set out in Schedule A, such party shall provide written notice
     thereof to the other party and the parties shall determine a reasonable
     corrective action plan and revised milestone schedule. The payment schedule
     set forth on Schedule C shall be revised appropriately to reflect the
     revised milestone schedule. If the parties are unable to agree to a
     reasonable corrective action plan or revised milestone schedules after good
     faith negotiations for a period of 15 days, either party may submit such
     matter to binding arbitration pursuant to the JAMS Streamlined Rules and
     Procedures (except that each side shall be entitled to take up to two
     depositions prior to the arbitration hearing), with such arbitration to be
     held in Boston, MA. The arbitration shall be held before one arbitrator
     with appropriate experience with respect to such dispute who shall be
     mutually agreed upon by the parties and if there is no agreement by the
     parties (within 10 days of submission to arbitration) then such arbitrator
     shall be selected pursuant to Rule 12 of the JAMS Streamlined Rules and
     Procedures. The arbitrator shall have the authority to modify the contract
     in a manner consistent with the arbitrator's resolution of such dispute and
     shall be entitled to use equitable remedies to enforce the arbitration
     decision. The arbitration decision may also be enforced by any court of
     competent jurisdiction. The costs (including attorneys fees) of the
     arbitration and the fees of the arbitrator shall be allocated as the
     arbitrator deems appropriate.

     After the Facility is completed, Nordion shall, in consultation with
     Molecular Insight Pharmaceuticals, develop and implement a Master
     Validation Plan that will allow the production of BMIPP under cGMPs for
     Clinical Trial supply and for Commercial Phase supply. Prior to
     implementation, both parties shall in writing approve the Master Validation
     Plan which approval will not be unreasonably withheld.

     The parties acknowledge and agree that Schedule A may be amended during the
     course of establishing the Facility to accommodate unforeseen events and
     results. All such changes to Schedule A shall be made by written agreement
     of the parties. If any change to Schedule A materially impacts the scope of
     work to be provided by Nordion, Nordion will provide a written estimate of
     the increase cost, which must be approved in advance by Molecular Insight
     Pharmaceuticals. No work on such scope change shall be carried out by
     Nordion prior to Nordion's receipt of Molecular Insight Pharmaceuticals'
     written approval of such change.

     The parties, upon signing this Agreement, shall each designate a program
     manager, who shall be responsible for coordinating communication and
     monitoring performance under this Agreement. The program managers

<PAGE>

                                        7

     shall meet monthly, in person or by telephone, for the purpose of reviewing
     the status of the project and assessing progress against the milestones and
     activities set forth in Schedule A. Minutes of meetings shall be prepared,
     maintained and provided to each of the parties. Prior to the monthly
     meetings, Nordion shall prepare and submit to Molecular Insight
     Pharmaceuticals a written report that sets forth in reasonable detail the
     progress of the Facility construction and indicates any problems that are
     known to Nordion or reasonably anticipated by Nordion to occur that either
     may result in the schedule for the Facility not being met in a timely
     manner or may result in a cost increase to be borne by Molecular Insight
     Pharmaceuticals.

3.2  USE OF THE FACILITY

     During the Term of this Agreement after transition to the Facility, Nordion
     shall ensure that the Facility is available for the production of BMIPP for
     supply to Molecular Insight Pharmaceuticals on an exclusive basis and
     Nordion shall only use the Facility for the production of BMIPP for
     Molecular Insight Pharmaceuticals. Nordion further agrees that it shall not
     (i) use other facilities for the production of BMIPP unless Molecular
     Insight Pharmaceuticals consents to the use of such other facilities in
     writing, such consent not to be unreasonably withheld, and (ii) manufacture
     BMIPP for any third party unless directed to do so in writing by Molecular
     Insight Pharmaceuticals.

3.3  MOLECULAR INSIGHT PHARMACEUTICALS RIGHT TO OBSERVE, INSPECT AND AUDIT

     During the Facility Program, upon ten (10) days prior written notice to
     Nordion, Molecular Insight Pharmaceuticals and any third-party consultant
     or auditor appointed by Molecular Insight Pharmaceuticals, such consultant
     and/or auditor being subject to a confidentiality agreement with and
     reasonably acceptable to Nordion, shall have reasonable access to observe
     and inspect the Facility for the purpose of determining the progress
     against Facility Milestones.

3.4  OWNERSHIP OF PHYSICAL ASSETS

     At all times Nordion will retain all right and title in and to the physical
     assets and real property that comprise the Facility and, for the purposes
     of this section 3.4, BMIPP and Molecular Insight Pharmaceuticals supplied
     components shall not be considered a physical asset. Upon the expiration or
     termination of this Agreement, Nordion, as owner of the Facility, shall be
     responsible for any and all costs, expenses and actions necessary in
     connection with the reconditioning, dismantling or disposing of the
     Facility or any parts thereof including, without limitation, any disposal,
     decommissioning or reclamation costs.

<PAGE>

                                       8

3.5  REPAIRS AND MAINTENANCE

     After the Facility is established, Nordion shall maintain such Facility in
     satisfactory operating condition as required by the FDA, Specifications,
     Process and cGMPs, and all other applicable laws, regulations, rules or
     orders.

     The cost of repairs, preventive maintenance and service contracts for the
     Facility shall be borne by Nordion.

        ARTICLE 4 - GENERAL MANUFACTURE AND SUPPLY OBLIGATIONS OF NORDION

4.1  BMIPP SUPPLY AND TRANSITION

     After the Facility is established, Nordion agrees to (i) use the Process to
     produce Batches of BMIPP (in quantities specified on Schedule D or Schedule
     E, as applicable) that meet the Specifications, FDA requirements and are
     manufactured in conformance with cGMPs and (ii) make arrangements for
     shipment of BMIPP to third parties on behalf of Molecular Insight
     Pharmaceuticals as directed by Molecular Insight Pharmaceuticals. All
     Batches shall be shipped in regulatory approved lead shields. Nordion
     reserves the right to withhold from shipment any Batch, or portion thereof,
     which does not conform to Specifications. Nordion, at the time of execution
     of this Agreement, may be supplying BMIPP from an alternative facility
     under the Development Agreement. After completion of the Facility Program
     pursuant to this Agreement and provided that Nordion is capable of
     manufacturing BMIPP in the Facility, Nordion shall transition manufacture
     BMIPP to the Facility established pursuant to this Agreement within thirty
     (30) days. Nordion shall provide written notice to Molecular Insight
     Pharmaceuticals of completion of the Facility.

4.2  FACILITY RESERVATION FEE

     After completion of the Master Validation Plan and commencing with the
     first full month after the date on which Nordion is ready to commence
     manufacture of BMIPP in the Facility (of which Nordion shall notify
     Molecular Insight Pharmaceuticals in writing), Molecular Insight
     Pharmaceuticals shall, during the remainder of the Term, pay to Nordion a
     Facility reservation fee of ** ("Facility Reservation Fee"), which fee
     shall not be refundable or reimbursable but shall be credited in a given
     month towards amounts owed by Molecular Insight Pharmaceuticals for the
     purchase of Batches in such month. Payment of the purchase price for
     Batches delivered in excess of the Facility

* confidential treatment requested *
<PAGE>

                                        9

     Reservation Fee in a given month shall be invoiced to Molecular Insight
     Pharmaceuticals.

4.3  CLINICAL TRIAL SUPPLY PRICING

     The price for a Batch supplied to Molecular Insight Pharmaceuticals for
     Clinical Trials shall be as set out in Schedule D and shall be payable as
     set forth in Section 4.8 herein.

4.4  COMMERCIAL PHASE PRICING

     Within thirty (30) days after completion of the Facility Program and
     Process scale up for Commercial Phase supply (of which Nordion shall notify
     Molecular Insight Pharmaceuticals in writing), the parties shall negotiate
     in good faith, for a period not to exceed thirty (30) days, the pricing
     terms for the supply of BMIPP to Molecular Insight Pharmaceuticals during
     the Commercial Phase. Indicative pricing for the supply of BMIPP during the
     Commercial Phase is outlined in Schedule E. Such indicative pricing shall
     only serve as the basis for negotiation and discussion and shall not be
     binding; provided, however, that if the parties are unable to agree to
     pricing terms at the end of such 30-day negotiation period, then the
     initial price for BMIPP during the Commercial Phase shall be the lesser of
     (i) ** as set forth on Schedule E or (ii)
     the highest price per dose offered by Nordion during such negotiation
     period. Once the parties have agreed upon the pricing terms, such terms and
     conditions shall be added to Schedule E and form a part of this Agreement.

4.5  COMPLIANCE WITH LAW; HANDLING OF BMIPP

     While Precursor, Reference Standards, Isotope, Excipients and BMIPP are in
     its possession or under its control, Nordion shall be responsible for
     compliance in all material respects with applicable statutory and
     regulatory requirements in the United States and Canada.

4.6  TESTING, DOCUMENTATION, AND QUALITY ASSURANCE

     Nordion shall maintain accurate and complete production records with
     respect to the Process, Batches and shipments, and Molecular Insight
     Pharmaceuticals shall have access to such records in order to determine
     that each Batch was produced, tested and prepared for shipment in
     compliance with all applicable laws, rules, regulations, as well as the
     Specifications and cGMP requirements.

     The tests and analyses provided in the Specifications as well as the nature
     and form of records may be amended by Nordion from time to time,

* confidential treatment requested *

<PAGE>

                                       10

     subject to the consent of Molecular Insight Pharmaceuticals, which shall
     not be unreasonably withheld after Nordion shall have delivered to
     Molecular Insight Pharmaceuticals, in writing, an explanation of such
     changes and why they are necessary or advisable. The parties agree to
     execute the Quality Agreement in substantially the form attached as
     Schedule "F". Nordion shall manufacture, test, pack and prepare for
     shipment, BMIPP in conformance with cGMPs and regulations applicable to the
     shipment of radioactive materials and subject to the Quality Agreement.

     Molecular Insight Pharmaceuticals shall be entitled to audit Nordion's
     quality assurance processes in accordance with the Quality Agreement.

4.7  LABELS

     Molecular Insight Pharmaceuticals shall be solely responsible for, and
     shall provide and approve the form and content of, the labels (except lot
     number and expiry date which shall be the responsibility of Nordion) to be
     applied to BMIPP. Label form and content (other than lot number and expiry
     date) shall remain the liability and exclusive property of Molecular
     Insight Pharmaceuticals. Such labels shall not be used by Nordion after
     termination or expiration of this Agreement and the label provided by
     Molecular Insight Pharmaceuticals may only be used by Nordion for the
     purpose of performing its obligations under this Agreement.

4.8  PAYMENT

     Nordion shall invoice Molecular Insight Pharmaceuticals for the purchase
     price of Batches of BMIPP and all undisputed amounts shall be paid by
     Molecular Insight Pharmaceuticals within thirty (30) days of the date of
     the invoice. Any undisputed amounts which remain unpaid after the
     aforementioned thirty (30) day period shall bear interest calculated
     monthly based on the prime lending rate as published by the Canadian
     Imperial Bank of Commerce in Ottawa, Ontario, plus 3%.

     In the event Molecular Insight Pharmaceuticals disputes any particular
     invoiced item or amount, Molecular Insight Pharmaceuticals shall pay the
     non-disputed portion of the invoice and the parties shall attempt in good
     faith to resolve the dispute pertaining to the balance within fifteen (15)
     days of receipt of the notice of dispute issued by either party. If the
     parties are unable to resolve such dispute after good faith negotiations
     for a period of 15 days, either party may submit such matter to binding
     arbitration pursuant to the JAMS Streamlined Rules and Procedures (except
     that each side shall be entitled to take up to two depositions prior to the
     arbitration hearing), with such arbitration to be held in Boston, MA. The
     arbitration shall be held before one arbitrator with appropriate

<PAGE>

                                       11

     experience with respect to such dispute who shall be mutually agreed upon
     by the parties and if there is no agreement by the parties (within 10 days
     of submission to arbitration) then such arbitrator shall be selected
     pursuant to Rule 12 of the JAMS Streamlined Rules and Procedures. The
     arbitrator shall have the authority to modify the contract in a manner
     consistent with the arbitrator's resolution of such dispute and shall be
     entitled to use equitable remedies to enforce the arbitration decision. The
     arbitration decision may also be enforced by any court of competent
     jurisdiction. The costs (including attorneys fees) of the arbitration and
     the fees of the arbitrator shall be allocated as the arbitrator deems
     appropriate. Nordion shall not be entitled to terminate this Agreement in
     connection with an invoice being disputed in good faith by Molecular
     Insight Pharmaceuticals.

     With respect to non-payment of undisputed amounts, Nordion shall not be
     entitled to suspend manufacturing activities or terminate this Agreement
     pursuant to section 14 unless and until the aggregate undisputed amount
     that is due and unpaid equals or exceeds US$100,000.00.

              ARTICLE 5 - GENERAL MOLECULAR INSIGHT PHARMACEUTICALS
                                   OBLIGATIONS

5.1  PRECURSOR, REFERENCE STANDARDS AND EXCIPIENTS

     Molecular Insight Pharmaceuticals or, at Molecular Insight Pharmaceuticals'
     discretion, its designee, shall provide to Nordion, at no charge,
     Precursor, Reference Standards and Excipients which meet the specifications
     in Schedule G in sufficient quantities to permit Nordion to meet its
     obligations hereunder. Nordion shall only use Precursor, Reference
     Standards and Excipients provided hereunder for the manufacture of BMIPP
     pursuant to this Agreement. Molecular Insight Pharmaceuticals shall at all
     times retain title in and to such materials in Nordion's possession.

5.2  UNAVAILABILITY OR SCARCITY OF PRECURSOR, REFERENCE STANDARDS OR EXCIPIENTS

     Molecular Insight Pharmaceuticals will notify Nordion upon Molecular
     Insight Pharmaceuticals becoming aware of a shortage of supply of
     Precursor, Reference Standards or Excipients, if such shortage will impact
     the manufacture of the BMIPP. Molecular Insight Pharmaceuticals shall not
     be liable for any delays or shortages in the supply of Precursor, Reference
     Standards or Excipients; provided, however, that any such shortages or
     delays in Precursor, Reference Standards or Excipients supply will not
     affect any amounts payable by Molecular Insight Pharmaceuticals pursuant to
     section 4.2 and shall excuse Nordion's performance of activities related to
     such Batch of BMIPP to the extent that

<PAGE>

                                       12

     Nordion's non-performance was caused by the Precursor, Reference Standards
     or Excipients supply delay or shortage and only for a period of time equal
     to the delay.

5.3  ADDITIONAL COMPENSATION TO NORDION

     In addition to the amounts set forth In Schedule C, Molecular Insight
     Pharmaceuticals will compensate Nordion based on the rate of ** per person
     per hour for the time spent by Nordion on the following activities only and
     upon Molecular Insight Pharmaceuticals prior written request:

     (i)  preparing and hosting Facility audits requested by Molecular Insight
          Pharmaceuticals including FDA preaudit inspections;

     (ii) preparing responses to FDA inquiries and preparation by Nordion of
          information requested by Molecular Insight Pharmaceuticals; and

     (iii) attending meetings with the FDA.

     Molecular Insight Pharmaceuticals shall reimburse Nordion for all
     reasonable costs incurred for travel and accommodation in carrying out the
     foregoing activities. Nordion shall provide an estimate of all such
     activities to Molecular Insight Pharmaceuticals prior to incurring the
     expenditure.

                           ARTICLE 6 - BMIPP SHIPMENTS

6.1  ORDERS AND SHIPMENTS

     During the Term of this Agreement, Molecular Insight Pharmaceuticals will
     forward orders to Nordion at its Ottawa, Ontario facility by facsimile or
     such other method as agreed by the parties. Each order will set forth the
     quantity of BMIPP to be produced and prepared for shipment, the identity of
     the recipient, delivery destination protocol number, IND/NDA number,
     applicable USNRC materials license number and IRS number. Delivery of BMIPP
     to Molecular Insight Pharmaceuticals or as otherwise directed by Molecular
     Insight Pharmaceuticals shall be Ex Works (Incoterms 2000) at Nordion's
     facility in Vancouver, British Columbia. Risk of loss of BMIPP shall pass
     to Molecular Insight Pharmaceuticals at point of delivery at Nordion's
     facility in Vancouver, British Columbia.

     During the Term of this Agreement Nordion shall use commercially reasonable
     best efforts to meet Molecular Insight Pharmaceuticals' orders and delivery
     requirements. Prior to the first shipment of BMIPP to any third party site,
     Molecular Insight Pharmaceuticals shall obtain from such third party and
     provide to Nordion such third party's license evidencing proper legal
     authority for the receipt and possession of BMIPP by such

* confidential treatment requested *
<PAGE>

                                       13

     third party. Molecular Insight Pharmaceuticals shall obtain all approvals,
     licenses and permits required to import BMIPP into the United States.
     Nordion shall make shipping arrangements with AirNet Express or such other
     carrier designated by Nordion and reasonably approved by Molecular Insight
     Pharmaceuticals. All BMIPP shipping costs incurred from the point of
     delivery transport vehicle Nordion's facility in British Columbia shall be
     borne by Molecular Insight Pharmaceuticals.

     Molecular Insight Pharmaceuticals shall be entitled to cancel any Batch
     ordered from Nordion by providing to Nordion at least two (2) business days
     written notice of cancellation prior to the later of commencement of
     production or the scheduled production date. The failure to give notice of
     cancellation hereunder shall result in Molecular Insight Pharmaceuticals
     being required to pay the full purchase price of such Batch to Nordion. All
     orders for BMIPP shall be forwarded by Molecular Insight Pharmaceuticals
     and received by Nordion by the Friday Noon (Eastern time) prior to the week
     in which BMIPP is to be manufactured.

6.2  LIMITED PRODUCT WARRANTY

     Nordion provides a product warranty, and does warrant for each Batch, that
     BMIPP will (i) conform with the Specifications, (ii) be manufactured,
     tested, processed, packed and prepared for shipment in accordance with
     cGMP's and (iii) be free from defects in material and workmanship for the
     period from the date of manufacture to the expiry date set out on each vial
     of BMIPP.

     If either party discovers that a Batch of BMIPP does not meet the
     Specifications, then the discovering party shall promptly communicate with
     the other party. All warranty obligations of Nordion with respect to a
     particular Batch shall cease and have no effect to the extent that any
     defect in such Batch arises from accident, abuse, misuse, alteration or
     gross negligence by Molecular Insight Pharmaceuticals or its suppliers. If
     Molecular Insight Pharmaceuticals determines that the failure to meet
     Specifications results from an act, failure to act or other fault of
     Nordion, or agent of Nordion, Nordion will promptly:

     (i)  replace such batch of BMIPP; and

     (ii) pay for shipping costs of replacement of BMIPP.

     In the event that Nordion reasonably disputes Molecular Insight
     Pharmaceuticals' determination that the fault is due to Nordion and/or its
     agent, the parties will select a mutually acceptable outside consulting
     firm which will be instructed to review the applicable information and data
     and confirm or dissent from Molecular Insight Pharmaceuticals'
     determination. If the consulting firm confirms Molecular Insight
     Pharmaceuticals'

<PAGE>

                                       14

     determination, Nordion will have the obligations set out in this section
     and Nordion will pay the fees of such consulting firm. If the consulting
     firm dissents from Molecular Insight Pharmaceuticals' determination or
     determines that the failure to meet Specifications was due to products,
     information or services supplied by Molecular Insight Pharmaceuticals,
     Nordion will not have the obligations set out in this section with respect
     to the disputed Batch and Molecular Insight Pharmaceuticals will pay the
     fees for such consulting firm.

                          ARTICLE 7 - LICENSE/OWNERSHIP

7.1  ROYALTY-FREE LICENSE

     Molecular Insight Pharmaceuticals hereby provides to Nordion a
     non-exclusive, nontransferable, royalty-free license during the Term of
     this Agreement to use Molecular Insight Pharmaceuticals Background
     Technology relating to BMIPP and the radiolabelling of Precursor with I-123
     for the sole purpose of assisting Nordion in carrying out its obligations
     set out in this Agreement.

7.2  OWNERSHIP

     Molecular Insight Pharmaceuticals Background Technology shall remain the
     sole and exclusive property of Molecular Insight Pharmaceuticals. Except to
     the extent that the Process is developed or contributed by Molecular
     Insight Pharmaceuticals, Molecular Insight Pharmaceuticals agrees and
     acknowledges that any and all ideas, know how, techniques, technology,
     methods, data, information, inventions or improvements that are conceived,
     written, created or first reduced to practice in the performance of the
     Process, the Nordion Background Technology and, subject to the limitations
     set forth in the second paragraph of this section 7.2, improvements to the
     Nordion Background Technology by Nordion or its employees shall be and
     remain the sole and exclusive property of Nordion.

     The parties acknowledge and agree that the process, to the extent jointly
     developed by Nordion and Molecular Insight Pharmaceuticals during the Term
     of this Agreement, whereby the Isotope is attached to the Precursor shall
     be proprietary technology jointly owned by both Nordion and Molecular
     Insight Pharmaceuticals and each party may continue to use and exploit such
     process as their own technology both during and after the Term of this
     Agreement.

     Nothing in this Agreement transfers or licenses any right, title or
     interest to Molecular Insight Pharmaceuticals Background Technology or
     Nordion Background Technology, except as expressly set out herein.

<PAGE>

                                       15

                  ARTICLE 8 - MOLECULAR INSIGHT PHARMACEUTICALS
                         REPRESENTATIONS AND WARRANTIES

8.1  MOLECULAR INSIGHT PHARMACEUTICALS' REPRESENTATIONS AND WARRANTIES

     Molecular Insight Pharmaceuticals represents, warrants and covenants that:

     (i)  it has full right, power and authority to enter into this Agreement;

     (ii) it is the owner or has the right of use of the Molecular Insight
          Pharmaceuticals Background Technology supplied to Nordion by Molecular
          Insight Pharmaceuticals to assist Nordion in manufacturing BMIPP and
          in carrying out its obligations hereunder;

     (iii) to Molecular Insight Pharmaceuticals' knowledge, there is no action
          or proceeding pending or, to its knowledge, threatened against
          Molecular Insight Pharmaceuticals before any court, administrative
          agency or other tribunal which would have an adverse material effect
          on its business or its ability to perform its obligations hereunder;

     (iv) it has the right to grant the license in section 7.1 and right to
          permit Nordion to use Molecular Insight Pharmaceuticals Background
          Technology to the extent required to assist Nordion in carrying out
          its obligations under this Agreement;

     (v)  it has not received any written notice of adverse claim or
          infringement of any patent or other intellectual property right, or
          misappropriation of trade secrets in connection with, the Molecular
          Insight Pharmaceuticals Background Technology or the use and
          exploitation of the Precursor, Reference Standard, Excipients or
          BMIPP;

     (vi) to Molecular Insight Pharmaceuticals' knowledge, making, using,
          offering for sale or selling of Precursor, Reference Standards,
          Excipients and BMIPP and the data, information, technology and know
          how used in the Process and manufacture of BMIPP contributed by
          Molecular Insight Pharmaceuticals do not infringe any valid third
          party patent, pending published patent application or other
          intellectual property right;

     (vii) it is not under any obligations, contractual or otherwise, to any
          other entity that might conflict, interfere or be inconsistent with
          any of the provisions of this Agreement;
<PAGE>

                                       16

     (viii) it shall obtain and maintain at its expense, all licenses, permits
          and approvals necessary for it to perform its obligations under this
          Agreement;

     (ix) as of the Effective Date, it is not currently subject to any
          proceeding pending or, to its knowledge, threatened for
          reorganization, liquidation or dissolution for the benefit of its
          creditors or otherwise;

     (x)  BMIPP shall not be misbranded within the meaning of the FD&C as a
          result of the application of the label content supplied by Molecular
          Insight Pharmaceuticals to Nordion pursuant to this Agreement, and
          BMIPP is not an article which may not be introduced into interstate
          commerce under the provisions of section 505 of the FD&C.

              ARTICLE 9 - NORDION'S REPRESENTATIONS AND WARRANTIES

9.1  REPRESENTATIONS AND WARRANTIES

     Nordion represents, warrants and covenants that:

     (i)  it has full right and authority to enter into this Agreement;

     (ii) it is the owner or has the right to use the Nordion Background
          Technology and other Nordion proprietary technology used during the
          Term of this Agreement;

     (iii) the Nordion Background Technology does not, to Nordion's best
          information and belief, infringe any patents, copyright or other
          industrial or intellectual property rights of third parties;

     (iv) it has not received any notice of adverse claim of infringement of any
          patent or other intellectual property right, or of misappropriation of
          trade secrets, in connection with the use and exploitation of the
          Nordion Background Technology;

     (v)  there is no action or proceeding pending or, to its knowledge,
          threatened against Nordion before any court, administrative agency or
          other tribunal which would have an adverse material effect on
          Nordion's business or its ability to perform its obligations
          hereunder;

     (vi) as of the Effective date, Nordion is not currently subject to any
          proceeding pending or, to its knowledge, threatened for
          reorganization, liquidation or dissolution for the benefit of its
          creditors or otherwise;

<PAGE>

                                       17

     (vii) it shall obtain and maintain, at its expense, all Facility licenses,
          permits and approvals necessary for it to manufacture BMIPP under this
          Agreement and shall provide Molecular Insight Pharmaceuticals with
          copies of such licenses, permits and approvals upon request;

     (viii) the BMIPP delivered pursuant to this Agreement shall, at the time of
          delivery by Nordion to Molecular Insight Pharmaceuticals, not be
          misbranded (to the extent branded by Nordion) or adulterated within
          the meaning of FD&C and effective at the time of delivery of the
          BMIPP.

                             ARTICLE 10 - INDEMNITY

10.1 INDEMNIFICATION BY MOLECULAR INSIGHT PHARMACEUTICALS

     Molecular Insight Pharmaceuticals agrees to indemnify, defend and hold
     Nordion and its Affiliates and their respective directors, officers,
     employees and agents, harmless from and against any damages, claims,
     liabilities and expenses (including, but not limited to, reasonable
     attorney's fees) resulting from any third party claims or suits ("General
     Claims Against Nordion") arising out of (a) Molecular Insight
     Pharmaceuticals' or a third party's use, handling or shipping of Reference
     Standards, Precursor, Excipients or BMIPP (including in the event that
     Nordion makes shipping arrangements on behalf of Molecular Insight
     Pharmaceuticals), (b) Molecular Insight Pharmaceuticals' breach of any of
     its material obligations, warranties or representations hereunder, or (c)
     Molecular Insight Pharmaceuticals' negligent acts or omissions or willful
     misconduct. Notwithstanding the foregoing, Molecular Insight
     Pharmaceuticals will not be required to indemnify, defend and hold Nordion
     and its Affiliates and their respective directors, officers, employees and
     agents harmless from and against any General Claims Against Nordion to the
     extent that such claims arise out of (i) Nordion's breach of any of its
     obligations, warranties or representations hereunder; (ii) Nordion's
     negligent acts or omissions or willful misconduct; (iii) any failure of
     Nordion to manufacture, handle, store, label, package, or prepare for
     shipment BMIPP in accordance with this Agreement, cGMPs or any other
     applicable laws, rules, regulations or other requirements of any applicable
     governmental entity; or (iv) any failure of Nordion to manufacture BMIPP
     consistent with the Specifications and requirements set forth herein.
     Notwithstanding anything in this section 10.1, "General Claims Against
     Nordion" shall not include "IP Claims Against Nordion" as described in
     section 10.3.

10.2 INDEMNIFICATION BY NORDION

<PAGE>

                                       18

     Nordion agrees to indemnify, defend and hold Molecular Insight
     Pharmaceuticals and its Affiliates and their respective directors,
     officers, employees and agents, harmless from and against any damages,
     claims, liabilities and expenses (including, but not limited to, reasonable
     attorney's fees) resulting from any third party claims or suits ("General
     Claims Against Molecular Insight Pharmaceuticals") arising out of (a)
     Nordion's manufacture, handling, storage, labeling, packaging or
     preparation for shipment of BMIPP; (b) Nordion's breach of any of its
     material obligations, warranties or representations hereunder; (c)
     Nordion's negligent acts or omissions or willful misconduct; or (d) any
     failure of the BMIPP to meet the Specifications. Notwithstanding the
     foregoing, Nordion will not be required to indemnify, defend and hold
     Molecular Insight Pharmaceuticals and its Affiliates and their respective
     directors, officers, employees and agents harmless from and against any
     General Claims Against Molecular Insight Pharmaceuticals to the extent that
     such claims arise out of (i) Molecular Insight Pharmaceuticals' breach of
     any of its obligations, warranties or representations hereunder; (ii)
     Molecular Insight Pharmaceuticals' negligent acts or omissions or willful
     misconduct; (iii) any defect or failure of Reference Standards, Precursor
     or Excipients to meet applicable specifications or (iv) Molecular Insight
     Pharmaceuticals' or third party's use, handling or shipment of Reference
     Standards, Precursor, Excipients or BMIPP. Notwithstanding anything in this
     section 10.2, "General Claims Against Molecular Insight Pharmaceuticals"
     shall not include "IP Claims Against Molecular Insight Pharmaceuticals" as
     described in section 10.4.

10.3 INTELLECTUAL PROPERTY CLAIMS AGAINST NORDION

     Molecular Insight Pharmaceuticals agrees to indemnify, defend and hold
     Nordion and its Affiliates and their respective directors, officers,
     employees and agents, harmless from and against any damages, claims,
     liabilities and expenses (including, but not limited to, reasonable
     attorneys' fees) resulting from any third party claims or suits arising out
     of any proceeding instituted by or on behalf of a third party based upon a
     claim that Molecular Insight Pharmaceuticals Background Technology, the
     Process (only to the extent contributed by Molecular Insight
     Pharmaceuticals), use or sale of the Reference Standards, Precursors,
     Excipients or BMIPP infringes a patent or any other intellectual property
     right of a third party in the United States or Canada ("IP Claims Against
     Nordion"). To the extent the Process or method of manufacture is developed
     or contributed by Nordion, Molecular Insight Pharmaceuticals will not be
     required to indemnify, defend or hold harmless Nordion or its Affiliates,
     and their respective directors, officers, employees and agents from and
     against IP Claims Against Nordion.

10.4 INTELLECTUAL PROPERTY CLAIMS AGAINST MOLECULAR INSIGHT PHARMACEUTICALS

<PAGE>

                                       19

     Nordion agrees to indemnify, defend and hold harmless Molecular Insight
     Pharmaceuticals and its Affiliates, and their respective directors,
     officers, employees and agents from and against any damages, claims,
     liabilities and expenses (including, but not limited to, reasonable
     attorney's fees) resulting from any third party claims or suits arising out
     of any proceeding instituted by or on behalf of a third party based upon a
     claim that the Nordion Background Technology, the method of manufacture of
     BMIPP or the Process to the extent developed or contributed by Nordion,
     infringes a patent or other intellectual property right of a third party in
     the United States or Canada ("IP Claims Against Molecular Insight
     Pharmaceuticals").

10.5 NORDION INFRINGEMENT

     In the event that any portion of the Nordion Background Technology,
     required in the manufacture of BMIPP, in the opinion of independent counsel
     mutually selected by the parties, becomes the subject of a valid claim for
     a patent, copyright or other intellectual property right infringement then
     Nordion shall, for a period of at least sixty (60) days after issuance of
     the opinion, use its commercially reasonable efforts to:

     i)   procure the right to continue using the technology, or

     ii)  modify the Nordion Background Technology to become non-infringing
          (with all Nordion costs, including any increase to the cost of the
          manufacturing of BMIPP by Nordion, to be borne by Nordion).

     After expiry of the sixty (60) day period from the issuance of the
     aforementioned opinion, if Nordion has been unable to remedy the
     infringement in accordance with subparagraph i) or ii) above, Molecular
     Insight Pharmaceuticals or Nordion, may upon written notice, suspend
     manufacturing activities and/or terminate this Agreement. The provisions of
     this section 10.5 are in addition to, and do not in any way limit, the
     indemnification obligations of Nordion set forth in this section 10.

10.6 MOLECULAR INSIGHT PHARMACEUTICALS INFRINGEMENT

     In the event that any portion of the Molecular Insight Pharmaceuticals
     Background Technology required in the manufacture of BMIPP, in the opinion
     of independent counsel mutually selected by the parties, becomes the
     subject of a valid claim for a patent, copyright or other intellectual
     property right infringement, then Molecular Insight Pharmaceuticals shall,
     for a period of at least sixty (60) days after issuance of the opinion, use
     its commercially reasonable efforts to:

<PAGE>

                                       20

     i)   procure the right to continue using the technology, or

     ii)  modify the Molecular Insight Pharmaceuticals Background Technology to
          become non-infringing provided such modification does not increase the
          cost of manufacture of BMIPP by Nordion (with all Molecular Insight
          Pharmaceuticals' costs including any increase to the cost of the
          manufacturing of BMIPP by Nordion to be borne by Molecular Insight
          Pharmaceuticals).

     After expiry of the sixty (60) day period from the issuance of the
     aforementioned opinion, if Molecular Insight Pharmaceuticals has been
     unable to remedy the infringement in accordance with subparagraph i) or ii)
     above, Nordion or Molecular Insight Pharmaceuticals may upon written
     notice, suspend manufacturing activities and/or terminate this Agreement.
     The provisions of this section 10.6 are in addition to, and do not in any
     way limit, the indemnification obligations of Molecular Insight
     Pharmaceuticals set forth in this section 10.

10.7 INDEMNIFICATION PROCEDURES

     A party (the "Indemnitee") intending to claim indemnification under this
     Agreement shall promptly notify the other party (the "Indemnitor") in
     writing of any action, claim or other matter in respect of which the
     Indemnitee or any of its directors, officers, employees or agents intend to
     claim such indemnification; provided, however, the failure to provide such
     notice within a reasonable period of time shall not relieve the Indemnitor
     of any of its obligations hereunder except to the extent the Indemnitor is
     materially prejudiced by such failure. The Indemnitor shall be entitled to
     control the defense of and/or settle any such action, claim or other
     matter. The Indemnitee agrees to the complete control of such defense or
     settlement by the Indemnitor, provided, however, any settlement of such
     claims shall require the Indemnitee's prior written consent unless such
     settlement includes a full release of the Indemnitee, in which case no
     consent shall be required. The Indemnitee and its directors, officers,
     employees and agents shall co-operate fully with the Indemnitor and its
     legal representatives in the investigation and defence of any action, claim
     or other matter covered by this indemnification. The Indemnitee shall have
     the right, but not the obligation, to be represented by counsel of its own
     selection and at its own expense.

                         ARTICLE 11 - REGULATORY MATTERS

11.1 REGULATORY STATUS

     Upon Nordion's reasonable request, Molecular Insight Pharmaceuticals shall
     provide updates to Nordion on submissions to the FDA and other

<PAGE>

                                       21

     jurisdictions and regulatory agencies for marketing authorization with
     respect to BMIPP.

11.2 MOLECULAR INSIGHT PHARMACEUTICALS RESPONSIBILITIES

     It shall be the responsibility of Molecular Insight Pharmaceuticals or its
     designee to file, obtain and maintain an IND/NDA, registrations, listings,
     authorizations and approvals as the FDA or any other applicable
     governmental entity may require to enable use of BMIPP in Clinical Trials
     and the Commercial Phase in the United States. Nordion shall provide
     directly to Molecular Insight Pharmaceuticals, or at Nordion's discretion
     for the purpose of protection of its proprietary technology with respect to
     the manufacture of the Isotope, directly to the regulatory authority (with
     a copy to Molecular Insight Pharmaceuticals purged of Nordion proprietary
     technology) all required information in its possession necessary to assist
     Molecular Insight Pharmaceuticals in filing, obtaining and maintaining all
     licenses, registrations, listings, authorizations and approvals of any
     governmental entities necessary for the use of BMIPP in support of
     Molecular Insight Pharmaceuticals' BMIPP IND/NDA submission.

11.3 NORDION RESPONSIBILITIES

     Nordion shall be responsible for obtaining and maintaining all necessary
     Facility licenses, registrations, authorizations and approvals which are
     necessary to develop, manufacture, handle, store, label, package and
     prepare for shipment BMIPP under cGMP conditions and other regulatory
     requirements including, but not limited to, the use and handling of
     radioactive materials.

     At Nordion's expense, Nordion shall update and maintain its existing I-123
     bulk chemical Drug Master File ("DMF") with the FDA as may be required for
     Molecular Insight Pharmaceuticals' IND/NDA for BMIPP. Nordion hereby grants
     Molecular Insight Pharmaceuticals a right of reference to such DMF, and
     upon request shall provide a letter of access to the DMF allowing
     regulatory review of the DMF by the FDA in conjunction with Molecular
     Insight Pharmaceuticals' BMIPP submissions.

11.4 GOVERNMENT INSPECTIONS, COMPLIANCE REVIEW AND INQUIRIES

     Upon request of any governmental entity or any third party entity
     authorized by a governmental entity, such entity shall, for the purpose of
     regulatory review, have access to observe and inspect the (i) Facility,
     (ii) procedures used for the storage of Reference Standards, Precursor and
     Excipients, and (iii) manufacturing, testing, storage and preparation for
     shipment of BMIPP, including Process development operations, and auditing
     the Facility for compliance with cGMP and/or other applicable

<PAGE>

                                       22

     regulatory standards. Nordion shall give Molecular Insight Pharmaceuticals
     prompt written notice of any upcoming inspections or audits by a
     governmental entity of the Facility or any of the foregoing and shall allow
     Molecular Insight Pharmaceuticals to participate in such audits by being
     present at any FDA close-out meeting and shall provide Molecular Insight
     Pharmaceuticals with a written summary of such inspection or audit
     following completion thereof. Notwithstanding the foregoing Molecular
     Insight Pharmaceuticals shall be entitled to have a representative in
     attendance at the Facility as an observer for the pre-approval inspection.
     Nordion agrees to use commercially reasonable efforts promptly to rectify
     or resolve any deficiencies noted by a government entity in a report or
     correspondence issued to Nordion. Subject to any specific arrangements
     agreed upon by the parties, Molecular Insight Pharmaceuticals shall be
     responsible for communicating with any governmental authority concerning
     the BMIPP or the marketing, distribution or sale of BMIPP, and Nordion
     shall, in accordance with the compensation rates set forth in section 5.3,
     provide Molecular Insight Pharmaceuticals with whatever assistance
     Molecular Insight Pharmaceuticals may reasonably require to assist it in
     such communications. Nordion shall have no such communications specifically
     related to BMIPP, except to the extent that they relate to Nordion's
     manufacturing activities under this Agreement, in which case Nordion shall
     be responsible for such communications. Notwithstanding the foregoing and
     except to the extent that an immediate communication is necessary under the
     circumstances or required by law, Nordion in good faith shall consult in
     advance with Molecular Insight Pharmaceuticals regarding all communications
     that relate to BMIPP or to Nordion's ability to manufacture BMIPP pursuant
     to this Agreement.

11.5 ACCESS TO THE FACILITY

     Molecular Insight Pharmaceuticals shall have reasonable access to the
     Facility at least once per calendar quarter. Molecular Insight
     Pharmaceuticals shall provide to Nordion at least five (5) business days
     prior written notice of requested access to the Facility for the purpose of
     this section. All such information disclosed to Molecular Insight
     Pharmaceuticals or its employees or agents, shall be deemed to be Nordion's
     Confidential Information as such term is defined in section 12.1 of this
     Agreement.

11.6 COMPLAINTS AND ADVERSE REACTIONS

     Nordion or Molecular Insight Pharmaceuticals shall provide to each other
     prompt notice of any information either of them receives regarding the
     safety of the Precursor, Reference Standards, Excipients, BMIPP or Isotope,
     including any confirmed or unconfirmed information regarding adverse,
     serious or unexpected events associated with BMIPP that may implicate the
     manufacture of BMIPP or one of its components; provided,

<PAGE>

                                       23

     however, that Molecular Insight Pharmaceuticals shall not be required to
     provide clinical trial reporting to Nordion. For serious or adverse events,
     notice must be given by telephone within one (1) business day after receipt
     of the information, followed immediately with written notice, advising the
     other of any adverse reaction or safety issues with respect to BMIPP of
     which it becomes aware, regardless of the origin of such information. Any
     other complaints shall be reported in writing to the other party on a
     weekly basis. Nordion agrees to co-operate with Molecular Insight
     Pharmaceuticals and any governmental entity in evaluating any complaint,
     claim, safety or adverse use report related to BMIPP. Nordion will provide
     timely assistance in responding to any complaints, including reviews of
     Batch records and retained samples as well as any necessary testing.

11.7 RECALLS

     Molecular Insight Pharmaceuticals shall notify Nordion promptly if BMIPP is
     the subject of a recall or correction (a "Recall"), and Molecular Insight
     Pharmaceuticals and/or its designee shall have sole responsibility for the
     handling and disposition of such Recall. Molecular Insight Pharmaceuticals
     and/or its designee shall bear the costs of any Recall of BMIPP unless and
     to the extent such Recall shall have been the result of Nordion's or its
     agents or employees acts or omissions or any product defects for which
     Nordion is responsible in which case Nordion shall to such extent be
     responsible for all of Molecular Insight Pharmaceuticals' reasonable
     out-of-pocket costs incurred for:

     (i)  notification of recall to Nordion and third parties;

     (ii) return shipment of any defective BMIPP to Nordion; and

     (iii) replacement of BMIPP.

     In the event that Nordion disputes Molecular Insight Pharmaceuticals'
     determination that the fault is due to Nordion and/or to its employees or
     agents, the parties will select a mutually agreeable outside consulting
     firm which will be instructed to review the applicable information and data
     and to confirm or dissent from Molecular Insight Pharmaceuticals'
     determination. If the consulting firm confirms Molecular Insight
     Pharmaceuticals' determination, Nordion will pay the fees of such
     consulting firm. If the consulting firm dissents from Molecular Insight
     Pharmaceuticals' determination Nordion will not have the obligations set
     forth herein with respect to the Recall and Molecular Insight
     Pharmaceuticals will pay the fees of such consulting firm. Molecular
     Insight Pharmaceuticals and/or its designee shall maintain records of all
     sales, shipping records of BMIPP and customers in sufficient detail to
     adequately administer a Recall for the period of time as required by
     applicable regulation.

<PAGE>

                                       24

11.8 NEW REGULATORY REQUIREMENTS

     Each party shall promptly notify the other of new regulatory requirements
     of which it becomes aware which are relevant to the manufacture of BMIPP
     under this Agreement and which are required by the FDA and other applicable
     governmental entities. The parties shall confer with each other with
     respect to the best means to implement and comply with such requirements.
     Any modifications or additions to the Facility required as a result of new
     regulatory requirements shall be borne by Molecular Insight
     Pharmaceuticals.

11.9 RECORDS

     Nordion shall maintain all records necessary to evidence compliance in all
     material respects with (i) all applicable laws, rules, regulations and
     other requirements of applicable governmental entities in the United States
     and Canada relating to the supply and manufacture of BMIPP; (ii) the
     Specifications; and (iii) material obligations under this Agreement. All
     such records shall be maintained by Nordion for at least two (2) years
     after termination or expiration of this Agreement. Nordion shall provide to
     Molecular Insight Pharmaceuticals reasonable access to such records upon
     request. Prior to destruction of any record after such time, Nordion shall
     give written notice to Molecular Insight Pharmaceuticals. Molecular Insight
     Pharmaceuticals shall have the right within thirty (30) days of receipt of
     such notice to request that Nordion maintain such records in an off site
     storage facility for such longer periods as Molecular Insight
     Pharmaceuticals requests, provided that Molecular Insight Pharmaceuticals
     pays all costs associated with such off site storage.

                          ARTICLE 12 - CONFIDENTIALITY

12.1 CONFIDENTIALITY AND EXCEPTIONS

     During the Term of this Agreement and for a period of ten (10) years
     thereafter, each party hereto shall maintain in confidence and not use or
     disclose to others for any purpose, other than to its employees or agents
     (which agents shall enter into a confidentiality agreement incorporating
     similar terms as set forth herein or be otherwise reasonably acceptable to
     the other party) with a need to know such information to perform such
     party's obligations under this Agreement or other than as expressly
     authorized in this Agreement, the content of the transactions contemplated
     herein, all technology including Molecular Insight Pharmaceuticals
     Background Technology, Nordion Background Technology and improvements
     thereto, and other information disclosed to such party by the other party
     which is identified as "Confidential Information" by the

<PAGE>

                                       25

     disclosing party (collectively "Confidential Information"). This obligation
     of confidentiality shall not apply to the extent that it can be established
     by the party in receipt of such information, that the information:

     (i)  was already known to the receiving party at the time of disclosure;

     (ii) was generally available to the public or otherwise part of the public
          domain at the time of its disclosure;

     (iii) became generally available to the public or otherwise part of the
          public domain after its disclosure to the receiving party through no
          act or omission of the receiving party;

     (iv) was disclosed to the receiving party by a third party who was not
          known to the receiving party to have obligations restricting
          disclosure of such information; or

     (v)  was independently developed by the receiving party without any use of
          Confidential Information of the disclosing party.

     Each party agrees that it will take the same steps to protect the
     confidentiality of the other party's Confidential Information as it takes
     to protect its own proprietary and confidential information, which shall in
     no event be less than commercially reasonable steps. Each party, and its
     employees and agents shall protect and keep confidential and shall not use,
     publish or otherwise disclose to any third party, except as permitted by
     this Agreement, or with the other party's written consent, the other
     party's Confidential Information.

     All Confidential Information supplied by one party to the other to assist
     in carrying out the obligations hereunder shall remain the property of such
     party and shall be returned to the other party upon termination or
     expiration of this Agreement.

                     ARTICLE 13 - DISCLOSURE OF INFORMATION

13.1 AUTHORIZED DISCLOSURE

     Notwithstanding section 12.1 each party may disclose Confidential
     Information to the extent such disclosure is reasonably necessary for
     prosecuting or defending litigation and/or complying with applicable
     government laws, rules or regulations, provided that if a party is required
     by law or regulation to make any such disclosure of the other party's
     Confidential Information, except where impracticable for necessary
     disclosure, for example in the event of medical emergency, it will give
     reasonable notice to the other party of such disclosure requirement and
     will use its reasonable efforts to secure a protective order or limit the
     extent of the information to be disclosed.

<PAGE>

                                       26

                        ARTICLE 14 - TERM AND TERMINATION

14.1 TERM

     This Agreement shall commence upon the Effective Date and, unless
     terminated earlier pursuant to this Agreement or extended upon mutual
     agreement of the parties, shall expire six (6) years after the Effective
     Date (the "Initial Term"). Thereafter, this Agreement shall automatically
     be renewed for successive additional two (2) year terms (each a "Renewal
     Term"). Either party may terminate this Agreement by providing two (2)
     years prior written notice to the other party during the Initial Term such
     termination to be effective upon expiry of the Initial Term at the 6th year
     anniversary or during any Renewal Term upon two (2) years prior written
     notice.

14.2 TERMINATION FOR BREACH

     Subject to section 4.8, this Agreement may be terminated by either party in
     the event of breach by the other party of a material term or condition
     hereof; provided, however, the other party shall first give to the
     breaching party written notice of the proposed termination of this
     Agreement (a "Breach Notice"), specifying the grounds therefore. Upon
     receipt of such Breach Notice, the breaching party shall have such time as
     necessary, but in any event not more than ninety (90) days, to cure such
     breach (or thirty (30) days with respect to a failure by Molecular Insight
     Pharmaceuticals to pay any undisputed amounts when due which, in the
     aggregate, exceed US$100,000 but excluding for this purpose all amounts
     which Molecular Insight Pharmaceuticals' in good faith disputes are due to
     Nordion which are subject to Section 4.8 herein). If the breaching party
     does not cure such breach within such cure period, the other party may
     terminate the Agreement without prejudice to any other rights or remedies
     which may be available to the non-breaching party.

     With respect to the supply of Batches of BMIPP by Nordion pursuant to
     orders placed pursuant to this Agreement, Nordion's failure to supply
     Batches in a timely manner and consistent with such orders and the
     Specifications shall not be considered a material breach by Nordion unless
     and until Nordion has failed, in any one year period, to fulfill more than
     four (4) Batch orders consistent with the Specifications, provided (i) the
     failure to supply is not attributable, in whole or in part, directly or
     indirectly, to Molecular Insight Pharmaceuticals and (ii) Nordion fails to
     supply a replacement Batch meeting the Specifications in accordance with
     this Agreement within one (1) week of the delivery date of the originally
     scheduled Batch (a "Supply Breach"). In the event of a Supply Breach,
     Molecular Insight Pharmaceuticals may terminate this Agreement upon thirty
     (30) days prior written notice to Nordion provided it gives written

<PAGE>

                                       27

     notice of termination to Nordion within sixty (60) days of the Supply
     Breach. Any failure by Nordion to manufacture or supply BMIPP due to a
     Force Majeure shall not be a material breach under this Agreement.

14.3 BANKRUPTCY

     This Agreement may be terminated by a party in the event the other party
     files a petition in bankruptcy, is adjudicated a bankrupt, makes an
     assignment for the benefit of its creditors, or otherwise seeks relief
     under or pursuant to any bankruptcy, insolvency or reorganization statute
     or proceeding, or if a petition in bankruptcy is filed against it which is
     not dismissed within ninety (90) days or proceedings are taken to liquidate
     the assets of such party.

14.4 REMEDIES UPON TERMINATION

     In the event of termination of this Agreement, in addition to any other
     remedies available to either of the parties:

     (i)  Nordion shall use reasonable efforts to terminate all activities under
          this Agreement immediately;

     (ii) within forty-five (45) days of such termination, at Molecular Insight
          Pharmaceuticals' request and expense, Nordion shall deliver to
          Molecular Insight Pharmaceuticals all data, documentation and other
          information belonging to Molecular Insight Pharmaceuticals pursuant to
          the terms of this Agreement;

     (iii) all licenses granted by Molecular Insight Pharmaceuticals to Nordion
          under this Agreement shall immediately terminate, and

     (iv) within sixty (60) days of such termination all Precursor, Reference
          Standards and Excipients remaining in inventory shall at Molecular
          Insight Pharmaceuticals' option and expense be disposed of or returned
          by Nordion to Molecular Insight Pharmaceuticals.

     Molecular Insight Pharmaceuticals shall pay to Nordion any amounts
     otherwise due within thirty (30) days of the date of termination.

                               ARTICLE 15 - SURVIVAL

15.1 CONSEQUENCES OR TERMINATION OR EXPIRATION

     All sections which by their nature must survive in order to give effect to
     their intent and meaning shall survive termination or expiration of this
<PAGE>

                                       28

     Agreement, including, without limitation, sections 3.4, 7.2, 10.1 - 10.4,
     10.7, 11.9, 12.1, 14.4, 17.1 and 21.1.

                              ARTICLE 16 - NOTICES

16.1 ANY NOTICE TO BE SENT TO A PARTY HEREUNDER SHALL BE FORWARDED TO:

     Nordion at:                       MDS Nordion
                                       447 March Road
                                       Ottawa, ON
                                       K2K 1X8

     Attention:                        Vice President, Products and Services
                                       Fax: 613-592-0767

     Molecular Insight Pharmaceuticals
     at:

                                       Molecular Insight Pharmaceuticals, Inc.
                                       160 Second Street
                                       Cambridge, MA

     Attention:                        Chief Operating Officer
                                       Fax: 617-492-5664

     Any notice required or authorized to be given by a party to the other in
     accordance with the provisions of this Agreement shall, unless otherwise
     specifically stipulated, be in writing and delivered personally, by a
     nationally recognized overnight courier, or if by electronic facsimile
     confirmed by certified or registered mail. Notice shall be deemed delivered
     upon receipt.

                         ARTICLE 17 - LIMITED LIABILITY

17.1 DISCLAIMER

     EXCEPT IN THE CASE OF THEIR RESPECTIVE INDEMNIFICATION OBLIGATIONS HEREIN,
     IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR INDIRECT,
     CONTINGENT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES, WHETHER IN
     CONTRACT, TORT, OR ANY OTHER CAUSE OF ACTION, EVEN IF ADVISED OF THE
     POSSIBILITY OF SUCH DAMAGES.

17.2 LIMITATION OF PRODUCT WARRANTY

     MOLECULAR INSIGHT PHARMACEUTICALS ACKNOWLEDGES THAT NORDION IS
     MANUFACTURING AND SUPPLYING BMIPP TO MEET SPECIFICATIONS. EXCEPT AS
     EXPRESSLY SET OUT IN THIS AGREEMENT, NORDION HEREBY DISCLAIMS ALL OTHER
     WARRANTIES OR CONDITIONS, WHETHER EXPRESS OR IMPLIED, STATUTORY

<PAGE>

                                       29

     OR OTHERWISE INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OR
     CONDITIONS OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

                             ARTICLE 18 - ASSIGNMENT

18.1 NO ASSIGNMENT

     This Agreement shall enure to the benefit of and shall be binding upon the
     heirs, executors, administrators, successors and permitted assigns of the
     parties. Neither Nordion nor Molecular Insight Pharmaceuticals shall assign
     this Agreement or any portion of this Agreement without the written
     approval of the other party, which approval shall not be unreasonably or
     untimely withheld; provided, however, that Molecular Insight
     Pharmaceuticals or Nordion may assign this Agreement without the other's
     consent in connection with the sale of all or substantially all of its
     assets or the business to which this Agreement pertains, to a third party
     or in connection with a merger, consolidation or similar transaction.

                             ARTICLE 19 - COMPLIANCE

19.1 COMPLIANCE WITH LAWS

     This Agreement and Nordion's and Molecular Insight Pharmaceuticals'
     obligations hereunder shall be carried out in all material respects in
     compliance with all applicable laws, by-laws, rules, regulations and orders
     of all applicable Federal, State, Provincial and Municipal governments.

                             ARTICLE 20 - NON-WAIVER

20.1 NON-WAIVER OF RIGHTS

     Failure by either party to enforce at any time any of the provisions of
     this Agreement shall not be construed as a waiver of its rights hereunder.
     Any waiver of a breach of any provision hereof shall not be effective
     unless in writing and shall not affect either party's rights in the event
     of any additional breach.

20.2 FORCE MAJEURE

     Neither party shall be liable to the other for failure to perform or delay
     in performing its obligations under this Agreement by virtue of the
     occurrence of an event of Force Majeure. In the event of Force Majeure, the
     party affected shall promptly notify the other and shall exert commercially
     reasonable efforts to eliminate, cure or overcome such event and to resume
     performance of its obligations. In the event such Force Majeure affecting
     either party continues for more than ninety (90) days

<PAGE>

                                       30

     the party not subject of the Force Majeure may, upon thirty (30) days
     written notice terminate this Agreement. "Force Majeure" shall mean an
     occurrence arising from unforeseen circumstances beyond a party's
     reasonable control which prevents, delays or interferes with the
     performance by such party of any of its obligations hereunder including
     without limitation an event that occurs by reason of any act of God, flood,
     power failure, fire, explosion, casualty or accident, or war, revolution,
     civil commotion, acts of public enemies, act of terrorism, blockage or
     embargo, interruption of or delay in transportation, strike or labor
     disruption.

                             ARTICLE 21 - INSURANCE

21.1 PRODUCT LIABILITY INSURANCE

     During the Term of this Agreement and for a period of one (1) year
     thereafter Molecular Insight Pharmaceuticals at its own expense shall
     provide and maintain a products liability insurance policy issued by a
     reputable insurance company with respect to BMIPP. Such policy shall add
     Nordion as an additional insured and shall have a limit of liability of not
     less than eight million United States dollars (US$8,000,000) per occurrence
     and in the aggregate. Molecular Insight Pharmaceuticals shall be solely
     responsible for any deductible or retention associated with this policy and
     such deductible or retention amounts shall not affect Nordion's interests.
     The policy shall contain a cross liability clause and shall provide for
     severability of interest such that breach of a policy condition committed
     by any one insured shall not adversely affect the rights of the other
     insured. Nordion shall be provided thirty (30) days' prior written notice
     of any material change to the policy and such change shall be subject to
     Nordion's prior written consent, which consent shall not be unreasonably
     withheld. Nothing contained in this section shall be deemed to limit in any
     way the indemnification provisions contained in this Agreement.

                            ARTICLE 22 - PUBLICATION

22.1 PUBLICITY

     The parties agree that, except as may otherwise be required by applicable
     laws, regulations, rules or orders or in connection with obtaining
     regulatory approvals for BMIPP, no information concerning this Agreement
     and the transactions contemplated herein shall be made public by either
     party without the prior written consent of the other, which consent shall
     not be unreasonably withheld or delayed. In the event either party decides
     to issue a press release announcing the execution of this Agreement, it
     shall not do so without the prior written approval of the other party.

<PAGE>

                                       31

     A copy of any proposed press release shall be provided to the other party
     for approval at least three (3) business days prior to any proposed
     release.

     In the event that this Agreement or any portion of its contents is required
     to be disclosed by Molecular Insight Pharmaceuticals or Nordion pursuant to
     Security Exchange Commission rules or regulations, the FDA, or other
     federal or state authorities, Molecular Insight Pharmaceuticals or Nordion,
     as the case may be, shall provide reasonable notice to the other prior to
     any such disclosure in order that, to the extent possible while enabling
     the party to comply with the applicable laws, rules and regulations.

                         ARTICLE 23 - DISPUTE RESOLUTION

23.1 DISPUTE RESOLUTION

     Except as otherwise set out, in the event that at any time during the Term
     of this Agreement, a disagreement, dispute, controversy or claim should
     arise the parties will attempt, in good faith, to resolve their differences
     for a period of thirty (30) days following written notice from one party to
     the other specifying such dispute(s). In the event the parties are unable
     to work out a resolution of the issue during such 30-day period, either
     party shall be free to take any action and seek any remedy it may have at
     law or in equity including specific performance and injunctive relief.

                       ARTICLE 24 - INDEPENDENT CONTRACTOR

24.1 NO JOINT VENTURE

     The parties agree that with respect to the transactions contemplated herein
     that they shall both be acting as independent contractors and nothing
     herein shall constitute the parties as entering into a joint venture or
     partnership, nor shall anything herein constitute either party as an agent
     of the other for any purpose whatsoever.

                            ARTICLE 25 - SEVERABILITY

25.1 INVALID PROVISIONS

     If any provision or term of this Agreement is found unenforceable under any
     of the laws or regulations applicable thereto, all other conditions and
     provisions of this Agreement shall nevertheless remain in full force and
     effect. Upon such determination that any term or other provision is
     invalid, illegal or incapable of being enforced, the parties hereto shall
     negotiate in good faith to modify this Agreement to effect the original
     intent of the parties as closely as possible in a mutually acceptable
     manner, in order

<PAGE>

                                       32

     that the transaction contemplated hereby be consummated as originally
     contemplated to the greatest extent possible.

                             ARTICLE 26 - AGREEMENT

26.1 ENTIRE AGREEMENT

     This Agreement, including the Schedules hereto which are incorporated
     herein, constitute the entire agreement of the parties with respect to the
     subject matter hereof and supersedes all proposals, oral or written, and
     all negotiations, conversations, or discussions, including, without
     limitation, the Development Agreement which is terminated upon transition
     of the manufacture of BMIPP under this Agreement pursuant to section 4.1.
     This Agreement may not be modified, amended, rescinded, canceled or waived,
     in whole or in part, except by written amendment signed by both parties
     hereto.

                                ARTICLE 27 - LAW

27.1 APPLICABLE LAW

     This Agreement shall be governed and construed in accordance with the laws
     of the Province of Ontario, without reference to its principles on conflict
     of laws. The application of the United Nations Convention for the
     International Sale of Goods is expressly excluded.

<PAGE>

                                       33

     IN WITNESS WHEREOF the parties hereto have executed this Agreement as of
the date first above written.

MDS Nordion, a division of MDS (Canada) Inc.

BY: /s/ Mike Thomas
    ------------------------------------
    Senior VP, Finance & Operations

Molecular Insight Pharmaceuticals, Inc.

By: /s/ John E. McCray
    ------------------------------------
    COO

68874

<PAGE>

                                       34

                                   SCHEDULE A

   DESCRIPTION OF FACILITY PROGRAM, FACILITY MILESTONES AND FACILITY SCHEDULE

FACILITY DESCRIPTION:

BMIPP will be manufactured in two newly constructed cells in a new section of
Nordion's Vancouver Operation building known as the RCA3 building, in basement
rooms 043 and 047. There will be one Class 10,000 cell for formulation with a
connecting cell with HEPA filtered clean zone for dispensing. Air filtration and
radiological containment will be achieved through HEPA filtration of inlet and
exhaust streams under negative pressure. These cells will be capable of holding
at least 10 Ci of I-123 in aggregate.

KEY DELIVERABLES:

1.   Two hot cells and related BMIPP production equipment

2.   A Class 10,000 clean room

3.   A primary anteroom (unclassified) and a gowning anteroom (class 100,000)

4.   An unclassified preparatory room adjacent to the clean room suite.

5.   A class 10,000 labeling cell with waste storage vault

6.   A class 10,000 dispensing cell with autoclave.

7.   One dose calibrator in each cell.

8.   A visual inspection station in each cell.

9.   A pot loading and extraction system for up to six F-335 lead pots at a time

10.  A Process Validation Summary Report.

<PAGE>

                                       35

COMMERCIAL PRODUCTION FACILITY:

                                   Cell View

                                  (CELL VIEW)

<PAGE>

                                       36

FACILITY DIAGRAM:

                               (FACILITY DIAGRAM)

<PAGE>

                                       37

FACILITY MILESTONES AND SCHEDULE

Milestones

The following milestones are critical to the schedule

     1) ** after Effective Date FAT (Factory
Acceptance Test) of Cells (fully assembled cells, at manufacturer, are inspected
for functionality and finish according to approved drawings.

     2) ** after Effective Date SAT (Site
Acceptance Test) of Cells. The cells are re-inspected after re-assembly at final
site.

     3) ** after Effective Date Facility Commissioning Substantially Complete.

     4) ** after Effective Date Equipment and Process Validation begins

     5) ** after Effective Date Validation executed,

     6) ** after Effective Date Project completion, submission

                                    SCHEDULE

                                   (SCHEDULE)

* confidential treatment requested *
<PAGE>

                                       38

                                   SCHEDULE B

                              BMIPP SPECIFICATIONS

                                   MDS NORDION
                              VANCOUVER OPERATIONS
                           FINAL PRODUCT SPECIFICATION

Issue No.: 0                       iodofiltic acid I-123              SPE-46-200
Effective: 2005.09.09                                                Page 1 of 2

PRODUCT                    : iodofiltic acid I-123
SYNONYMS                   : [I-123] - 15-(p-iodophenyl)-3-methylpentadecanoic
                             Acid or I-123 BMIPP
VISUAL INSPECTION          : Clear, colourless solution, essentially free of
                             foreign matter visible in the unaided eye.
RADIONUCLIDE IDENTITY      : Gamma-Photon emission at 159 +/- 2 keV
RADIONUCLIDIC PURITY       : > or = 99.8% I-123
RADIOACTIVITY
   CONCENTRATION           : 2.25 to 2.75 mCi/mL**
RADIOCHEMICAL IDENTITY     : *Rr value between 0.95 to 1.05
RADIOCHEMICAL PURITY       : > or = 95% as iodofiltic acid I-123
CHEMICAL PURITY
   BMIPP                   : 0.225 to 0.275 mg/mL
   UDCA                    : 3.15 to 3.85 mg/mL
TOTAL ACTIVITY             : 4.5 to 5.5 mCi at TOC**
PH                         : 8.2 to 9.2
BACTERIAL ENDOTOXIN        : < or = 17.5 EU/mL
STERILITY                  : Meets USP requirements - test initiated on day of
                             manufacture
EXPIRY                     : 1200 PT two days after date of manufacture

*    Rr is the retention time of the product (iodofiltic acid I-123) divided by
     the retention time of the reference standard (non-radioactive Iodofiltic
     acid)

**   Toc = Time of Calibration; 1500 h PT, one day after date of manufacture.

                                UNCONTROLLED COPY

<PAGE>

                                       39

Issue No.: 0                       iodofiltic acid I-123              SPE-46-200
Effective: 2005.09.09                                                Page 2 of 2

Prepared by /s/ Illegible                              Date: (Illegible)
            ----------------------------------------

Approved by /s/ Illegible                              Date: (Illegible)
            ----------------------------------------
            Production

Approved by /s/ Illegible                              Date: 2005/8/31
            ----------------------------------------
            Quality

Approved by /s/ James Wachholz                         Date: 2005 Sept 07
            ----------------------------------------
            Molecular Insight Pharmaceuticals, Inc.

<PAGE>

                                       40

                                   SCHEDULE C

                           FACILITY CONSTRUCTION FEES

1.   FEES

<TABLE>
<S>                                      <C>
1. Engineering and Documentation             **
2. Facility Construction                     **
3. Cell and Ancillary Equipment              **
4. Master Validation Plan program            **
5. BMIPP Equipment                           **
                                         ------
   Total                                     **
                                         ======
</TABLE>

Notes: 1. All fees are in United States dollars

2.   PAYMENT SCHEDULE

1.   ENGINEERING & DOCUMENTATION

** on Effective Date

** on Issuance of Project Status Report at Factory Acceptance Testing of the
    cells

** on Facility Commissioning

2.   FACILITY CONSTRUCTION

** on Effective Date

** on Commencement of Facility Construction

** on Completion of Facility Construction

3.   CELL AND ANCILLARY EQUIPMENT

** on Effective Date

** on Factory Acceptance Testing of the Cells

** on completion of Construction of the Facility

4.   VALIDATION PROGRAM

** on Effective Date

** on Facility Commissioning

** on Master Validation Plan program Completion

5.   BMIPP PROCESS EQUIPMENT

** on Effective Date

** on Installation of BMIPP Process Equipment

** on Facility Commissioning

* confidential treatment requested *

<PAGE>

                                       41

                                   SCHEDULE D

                   PRICES OF BATCHES FOR CLINICAL TRIAL SUPPLY

A.   1 CI BATCH OF BMIPP

Price: Year 1 supply of BMIPP under this Agreement ** per Batch
       Year 2 supply: **
       Year 3 supply: **
       Year 4 supply: **
       Year 5 supply: **

B.   2 CI BATCH OF BMIPP

Price: TBD after development work completed.

Notes:

1. 1 Ci Batch is approximately 30 doses of BMIPP (as defined in Schedule B) of
which 20 are shippable and 10 are retained by Nordion for archival and quality
assurance testing purposes only.

2. The All Items Canadian Consumer Price Index ("CPI") will be based on the
percentage increase in the CPI for the twelve (12) month period ending three (3)
months prior to such anniversary as published in the Canadian Government annual
reports.

* confidential treatment requested *
<PAGE>

                                       42

                                   SCHEDULE E

             INDICATIVE PRICING OF BMIPP FOR COMMERCIAL PHASE SUPPLY

As per section 4.4 of the Agreement, the indicative price of BMIPP for supply
during the Commercial Phase shall be subject to negotiation and is estimated to
be initially **; provided further that the initial purchase price shall not
exceed **.

This indicative price is based on the following assumptions.

1.   Commercial Phase Batch size is ** doses of BMIPP, of which ** doses will be
     available for purchase and shipment and 24 doses (including rejects up to
     5%) shall be retained by Nordion for archival and quality assurance testing
     purposes only.

2.   Total doses of BMIPP purchased by Molecular Insight Pharmaceuticals is **
     per Commercial Phase Batch of which there shall be at least ** Commercial
     Phase Batches produced per week.

3.   Overall process yield/efficiencies is **

4.   Dose size is 5 mCi and is calibrated to 3 PM PT the day after manufacture.

* confidential treatment requested *
<PAGE>

                                QUALITY AGREEMENT

                         INTERCOMPANY QUALITY AGREEMENT

                     MOLECULAR INSIGHT PHARMACEUTICALS, INC.
                          having a place of business at
                                160 Second Street
                       Cambridge Massachusetts, 02142 USA
            (hereinafter called "Molecular Insight Pharmaceuticals")

                                       AND

                                   MDS NORDION
                         Ottawa, Ontario, Canada K2K 1X8
                          (hereafter called "Nordion")

Approved by: /s/ Illegible                             Date: 01 FEB 2006
            ----------------------------------------
            Molecular Insight Pharmaceuticals, Inc.
            Director of Quality Assurance

Approved by: /s/ Illegible                             Date: 2006/2/1
            ----------------------------------------
            MDS Nordion
            Director, Quality, Safety and Regulatory
            Affairs

<PAGE>

                              HISTORY OF REVISIONS

<TABLE>
<CAPTION>
REVISION VERSION   REVISION DATE   REVISED BY   DESCRIPTION
----------------   -------------   ----------   -----------
<S>                <C>             <C>          <C>
        0                                         ORIGINAL
</TABLE>

Intercompany Quality Agreement                                             Rev.0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.             Page 3 of 28

<PAGE>

1    QUALITY AGREEMENT

     1.1  PURPOSE

          This agreement defines how Nordion and Molecular Insight
          Pharmaceuticals will interact with each other and describes the
          responsibilities of each.

     1.2  RELATIONSHIP TO SUPPLY AGREEMENT

          1.2.1 This agreement shall be considered a Schedule to the BMIPP
               Supply Agreement and all capitalized terms not defined herein
               shall have the meaning set forth in the BMIPP Supply Agreement.

          1.2.2 In the event of a conflict between any of the provisions of the
               Quality Agreement and the BMIPP Supply Agreement, the provisions
               of the BMIPP Supply Agreement shall govern.

     1.3  GUIDING PRINCIPLES REGARDING WORKING RELATIONSHIPS BETWEEN NORDION AND
          MOLECULAR INSIGHT PHARMACEUTICALS.

          1.3.1 Molecular Insight Pharmaceuticals has the responsibility to
               provide sufficient information to Nordion so that Nordion can
               operate within the parameters of the IND/NDA applications.

          1.3.2 Nordion has the responsibility to manufacture and test BMIPP in
               accordance with the Supply Agreement and the registration
               documentation provided by Molecular Insight Pharmaceuticals and
               shall supply BMIPP that is manufactured and tested in accordance
               with the IND/NDA, which shall include all product specifications
               and instructions and cGMPs.

2    PRODUCT

     This agreement covers the manufacture of BMIPP in accordance with the
     Specifications set out in Nordion's specification #SPE-46-200 iodofiltic
     acid I-123 (see Appendix I).

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.             Page 3 of 28
<PAGE>

3    QUALITY REPRESENTATIVES

     The Quality Representatives for each party shall have the responsibility of
     ensuring that all actions of their company indicated in this agreement, are
     performed as specified.

     Molecular Insight Pharmaceuticals Quality Representative:
     Jeff Priem
     Director of Quality Assurance
     Work: (617) 492-5554

     Nordion Quality Representative:
     Brian Abeysekera
     Director, Quality, Safety and Regulatory Affairs
     Work: (604) 228-5981

4    DURATION OF AGREEMENT

The agreement will expire concurrently with termination of the BMIPP Supply
Agreement. This agreement can be revised, as needed, with the written approval
of both Quality Representatives.

5    MANUFACTURING CGMP COMPLIANCE

     5.1  PREMISES

          5.1.1 Nordion will manufacture BMIPP at facilities located at:
               Vancouver, British Columbia, Canada

          5.1.2 The premises and the equipment used to manufacture and test
               BMIPP will be compliant with the then current regulatory
               requirements set forth in section 5.2 below and the provisions of
               the Supply Agreement.

          5.1.3 Nordion will maintain controlled access to the premises. All
               visitors must sign-in and shall be escorted during any visit to
               the areas of the premises used to manufacture, test, and store
               BMIPP. BMIPP shall be manufactured in the Facility referenced in
               the Supply Agreement and schedules thereto and such manufacture
               shall utilize equipment suitable for the manufacture of-BMIPP.

          5.1.4 Nordion will procure all materials and components necessary to
               manufacture BMIPP, except that Precursor and Reference Standards
               and Excipient (UDCA) shall be supplied by Molecular Insight
               Pharmaceuticals.

          5.1.5 Nordion is responsible for ensuring that all materials and
               components procured for the manufacture of BMIPP meet the written
               specifications, including cGMPs, for the materials and
               components.

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.             Page 4 of 28

<PAGE>

5.2  CGMP GUIDELINES

     The principles detailed in the United States Current Good Manufacturing
     Practices (21 CFR, parts 210 and 211), as amended from time to time, will
     cover the standards of manufacture of BMIPP, as well as the product
     specifications and any applicable product license.

5.3  BATCH NUMBERS

     The convention for the Batch Identification Number will follow Nordion's
     system, and will provide a unique identifier to each Batch (BMI-XY-ABC).
     The alphanumeric description will be a three letter prefix "BMI" followed
     by a two digit year code (i.e., 05 for 2005), and a three digit sequential
     number that would be unique for the batch (i.e., 001).

  6   QUALITY CONTROL CGMP COMPLIANCE

     6.1  GENERAL

          The testing activities for BMIPP are defined in the BMIPP Product
          Release Forms (see Appendix 2). Nordion is responsible for ensuring
          all test samples have been obtained and all required testing
          activities have been completed for BMIPP prior to shipment These
          activities must ensure that BMIPP meets the requirements as defined in
          the approved product Specifications and the Supply Agreement. See
          Appendix 2 - PRF-46-001A Product Release Form for [I-123]-BMIPP and
          PRF-46-001B Product Release Form for [I-123]-BMIPP.

     6.2  BMIPP TESTING

          6.2.1 Nordion will perform all required raw material, in-process and
               BMIPP testing using approved sampling plans, test methods and
               specifications. Sampling plans and test methods shall be jointly
               established by Nordion and Molecular Insight Pharmaceuticals and
               approved in advance by Molecular Insight Pharmaceuticals.

          6.2.2 Nordion-will supply a copy of each completed Batch BMIPP Release
               Form, which form shall include product testing data and results
               as well as notification of any errors or deviations, to Molecular
               Insight Pharmaceuticals within 1 day after such form is
               completed.

     6.3  RETAIN SAMPLES

          Nordion is responsible for retaining and maintaining BMIPP samples per
          regulatory requirements.

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.             Page 5 of 28

<PAGE>

     6.4  STABILITY PROGRAM

          6.4.1 Nordion is responsible for maintaining the stability program per
               regulatory requirements. See Appendix 3 - STM-46-002 Stability
               Protocol for iodofiltic acid I-123 and ACR-46-002 Stability
               Protocol for iodofiltic acid I-123.

          6.4.2 Stability Failures - Any confirmed problems that arise as a
               result of the stability program will be immediately communicated
               in writing by Nordion to Molecular Insight Pharmaceuticals.

     6.5  OUT-OF-SPECIFICATION (OOS) INVESTIGATIONS

          Any test result that indicates the requirement(s) detailed in an
          approved Nordion material specification is not being met, will be
          investigated by Nordion within 24 hours and resolved within 30 days
          thereafter. All OOS results that are confirmed or are inconclusive
          must be reported to Molecular Insight Pharmaceuticals as detailed
          under section 7.1.2 below. Nordion is responsible for carrying out the
          OOS investigation that is in accordance with the applicable
          regulations and the Supply Agreement. In no case will Nordion release
          any BMIPP for shipment with a confirmed out-of-specification result.

7    QUALITY ASSURANCE

     7.1  BMIPP MANUFACTURING ERRORS, DEVIATIONS, AND NON-CONFORMANCES

          7.1.1 Any error or deviation from specifications in the manufacture or
               testing of BMIPP must be carefully explained and documented in
               writing. This documentation must be included in the Batch record
               for affected BMIPP and retained for 7 years by Nordion.

          7.1.2 Nordion shall notify Molecular Insight Pharmaceuticals within 1
               days of occurrence in the event of any deviations or significant
               problems during manufacturing and when any test reveals
               contamination, lack of sterility assurance or BMIPP performance
               problems. Any significant deviation must be reviewed and approved
               by Molecular Insight Pharmaceuticals. The disposition of any
               BMIPP batch(s) implicated in such deviations or significant
               problems shall be agreed jointly between Nordion and Molecular
               Insight Pharmaceuticals.

          7.13 Nordion will notify Molecular Insight Pharmaceuticals in writing
               within 24 hours of discovery of any problems that may impact any
               Batch previously shipped.

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.             Page 6 of 28

<PAGE>

     7.2  PRODUCT RELEASE

          Prior to release, all manufacturing and testing documentation
          associated with any Batch is reviewed to ensure all steps were carried
          out as described and that all in-process parameters were within
          specification. The results of the testing are reviewed to determine if
          BMIPP meets Specification. The Batch BMIPP Product Release Form serves
          as a checklist to ensure all documentation associated with manufacture
          and testing of the Batch is present, and provides the acceptable
          limits for test results as derived from BMIPP Specification.

     7.3  PRODUCT RECALL

          7.3.1 Nordion is responsible for providing any and all data or
               information related to BMIPP recalls within an agreed upon time
               frame not to exceed 1 day. Molecular Insight Pharmaceuticals and
               Nordion will consult and cooperate on any recall decision with
               the goal of reaching an agreement; however, Molecular Insight
               Pharmaceuticals has the final decision on recalling its product.
               Additional provisions pertaining to recalls are set forth in
               section 11.7 of the Supply Agreement.

          7.3.2 Both parties must forward to the other party a copy of any
               regulatory field alerts before or at the time that the alert is
               sent to the Regulatory Authorities. Molecular Insight
               Pharmaceuticals has final responsibility on the decision to
               submit a field alert.

     7.4  DOCUMENTATION

          7.4.1 Originals of all Batch documents and associated quality control
               records including raw materials records will be retained by
               Nordion as per Nordion procedure. In any case, Nordion will
               consult with Molecular Insight Pharmaceuticals prior to
               destruction of any BMIPP related records. See Appendix 4 -
               SOP-80-005 Quality Records and DCS-76-004 QRRMF: Batch Records
               (Radiopharmaceuticals)

          7.4.2 In the case of a specific request from Molecular Insight
               Pharmaceuticals, Nordion agrees to provide at a mutually agreed
               cost a copy of any of the following Batch documents for BMIPP, by
               facsimile or courier:

               -    Analytical and microbiological test results (finished
                    product and in-process).

               -    Deviation Reports

               -    Executed Batch Record

               -    Investigation Reports as it relates to a BMIPP batch

               -    Label Room Samples

               -    Line Clearances

               -    Reconciliation Sheets

               -    Reject Records

               -    Weighing Records

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.             Page 7 of 28

<PAGE>

8    REGULATORY CMC COMPLIANCE

     8.1  Regulatory Correspondence and Inspections will be governed by section
          11.4 of the Supply Agreement.

     8.2  REGULATORY ACTIONS

          8.2.1 Molecular Insight Pharmaceuticals will promptly notify Nordion
               of any regulatory actions related to BMIPP that may impact
               Nordion.

          8.2.2 Nordion and Molecular Insight Pharmaceuticals agree to supply
               each other with any manufacturing, testing, or storage data
               within 1 business day, if requested, as the result of a
               regulatory inspection, or a potential regulatory exposure such as
               a recall or significant product complaint.

     8.3  RIGHT OF MOLECULAR INSIGHT PHARMACEUTICALS TO AUDIT

          8.3.1 In addition to all audit and inspection rights set forth in the
               Supply Agreement, not more often than once per year, except as
               set out in 8.3.2 and provided reasonable notice in writing
               (minimum of 5 business days) is provided, Nordion will allow
               qualified, pre-approved representatives from Molecular Insight
               Pharmaceuticals to have access to the manufacturing, warehousing,
               laboratory premises and records to perform one standard "cGMP
               systems" audit. Molecular Insight Pharmaceuticals representatives
               will be escorted at all times by Nordion personnel.

          8.3.2 Nordion will permit Molecular Insight Pharmaceuticals
               representatives to conduct "for cause" audits as necessary,
               provided written notification is provided at least 3 business
               days in advance, to address significant product quality or safety
               problems and may have access to all related information.

          8.3.3 Nordion and Molecular Insight Pharmaceuticals shall agree on a
               mutually acceptable course of corrective action and resolution of
               the issues, in the event that Molecular Insight Pharmaceuticals
               finds any deficiencies during any such audits.

     8.4  MOLECULAR INSIGHT PHARMACEUTICALS AUDIT CLOSEOUT

          8.4.1 An exit meeting will be held with representatives from Nordion
               and Molecular Insight Pharmaceuticals to discuss significant
               audit observations.

          8.4.2 Molecular Insight Pharmaceuticals will provide a written report
               of all observations within 30 days to Nordion. Nordion will
               provide a written response to the report. The response will
               detail corrective action for each observation, if required. Due
               to the potential complexity of the observations and subsequent
               planning, Nordion will make every effort to ensure the response
               back to Molecular Insight Pharmaceuticals is completed within 30
               to 60 days of the audit report receipt. Nordion will follow up to
               ensure that all corrective actions are implemented.

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.             Page 8 of 28

<PAGE>

9    NON-CONFORMITY DISPUTE RESOLUTION

     In the event that a dispute arises between Nordion and Molecular Insight
     Pharmaceuticals in the non-conformity of a Batch with respect to its
     release, the Quality Representatives from both companies shall, in good
     faith, promptly attempt to reach an agreement. Whatever the outcome, either
     party has the right of veto to reject a BMIPP batch or a portion thereof
     based upon a quality issue.

10   CHANGE MANAGEMENT

     10.1 Any process changes, including, without limitation, those covering
          specifications, manufacturing processes, test methods and their
          associated facilities, equipment and utilities proposed by either
          Molecular Insight Pharmaceuticals or Nordion will be communicated to
          the other party for initial review and written approval of such
          changes. This will enable Nordion and Molecular Insight
          Pharmaceuticals to assure changes are handled in compliance with
          applicable regulatory requirements and will allow Nordion to maintain
          adequate control over the quality commitments in the NDA/sNDA
          application made to the FDA by Molecular Insight Pharmaceuticals.

     10.2 Nordion is responsible for implementing compendial changes of the
          ingredients utilized in the manufacture of the product and for
          notifying Molecular Insight Pharmaceuticals of any required changes.

     10.1 All proposed changes reported to Molecular Insight Pharmaceuticals by
          Nordion must go through a technical and regulatory impact assessment
          by Molecular Insight Pharmaceuticals. This impact assessment will be
          carried out within seven business days. In the event this timeline
          cannot be met, Molecular Insight Pharmaceuticals will advise Nordion
          and will provide an estimated turnaround time. Any changes that are
          identified by Molecular Insight Pharmaceuticals as having a direct
          impact on either their regulatory submission or the performance of
          BMIPP, must be documented, and notification sent back to Nordion. The
          change(s) must receive written approval from the Molecular Insight
          Pharmaceuticals Quality and Regulatory representative prior to
          implementation. Molecular Insight Pharmaceuticals is responsible for
          reporting all changes to FDA.

     10.2 Where required, following validation of a process change, Nordion will
          supply a copy of the related validation summary report to Molecular
          Insight Pharmaceuticals and, if applicable, copies of associated
          stability data as it becomes available.

11   VALIDATION OF THE PROCESS

     11.1 Nordion is responsible for ensuring that the Process and all testing
          associated with the BMIPP is validated pursuant to validation protocol
          previously approved in writing by Molecular Insight Pharmaceuticals.
          The validation should ensure that the process is capable of
          consistently meeting the predetermined release specifications for the
          product.

     11.2 Nordion will provide Molecular Insight Pharmaceuticals access to all
          validation protocols related to the BMIPP (with any proprietary
          information redacted) for audit purposes.

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.             Page 9 of 28
<PAGE>

                                   APPENDIX 1
                           FINAL PRODUCT SPECIFICATION

                                   MDS NORDION
                              VANCOUVER OPERATIONS
                           FINAL PRODUCT SPECIFICATION

Issue No.: 0                       iodofiltic acid I-123              SPE-46-200
Effective: 2005.09.09                                                Page 1 of 2

Product                       : iodofiltic acid I-123

Synonyms                      : [I-123] - 15-(p-iodophenyl)-3-
                                methylpentadecanoic Acid or I-123 BMIPP

Visual Inspection             : Clear, colourless solution, essentially free of
                                foreign matter visible to the unaided eye.

Radionuclide Identity         : Gamma-Photon emission at 159 +/- 2 keV

Radionuclidic Purity          : > or = 99.8% I-123

Radioactivity Concentration   : 2.25 to 2.75 mCi/mL**

Radiochemical Identity        : *Rr value between 0.95 to 1.05

Radiochemical Purity          : > or = 95% as iodofiltic acid I-123

Chemical Purity
   BMIPP                      : 0.225 to 0.275 mg/mL
   UDCA                       : 3.15 to 3.85 mg/mL

Total Activity                : 4.5 to 5.5 mCi at TOC**

pH                            : 8.2 to 9.2

Bacterial Endotoxin           : < or =  17.5 EU/mL

Sterility                     : Meets USP requirements - test initiated on day
                                of manufacture

Expiry                        : 1200 PT two days after date of manufacture

*    Rr is the retention time of the product (iodofiltic acid I-123) divided
     by the retention time of the reference standard (non-radioactive
     iodofiltic acid)

**   TOC = Time of Calibration; 1500 h PT, one day after date of manufacture.

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 10 of 28

<PAGE>

                               APPENDIX 1 - CONT.
                           FINAL PRODUCT SPECIFICATION

Issue No.: 0                       iodofiltic acid I-123              SPE-46-200
Effective: 2005.09.09                                                Page 2 of 2

Prepared by: /s/ Illegible                             Date: 2005. 08.30
             ---------------------------------------

Approved by: /s/ Illegible                             Date: (Illegible)
             ---------------------------------------
             Production

Approved by: /s/ Illegible                             Date: 2005/8/31
             ---------------------------------------
             Quality

Approved by: /s/ Illegible                             Date: 2005 Sept 07
             ---------------------------------------
             Molecular Insight Pharmaceuticals, Inc.

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 11 of 28

<PAGE>

                                   APPENDIX 2
                             PRODUCT RELEASE FORMS

                                                     Each page of the document
                                                     has been checked against
                                   MDS NORDION       the master copy for
                              VANCOUVER OPERATIONS   accuracy
                              PRODUCT RELEASE FORM
                                                     (Illegible)

                                                     Date: ___________________

Issue No.: 1                       Product Release Form              PRF-16-001A
Effective: 2005.09.14           for iodofiltic acid I-123            Page 1 of 2

<TABLE>
<S>                      <C>                            <C>
LOT NO.: _______         BMI- ___ - _________           QC Lab No.: __________________
Production Date: ________________                       [ ] Release   [ ] Reject
Calibration Date: 1500 PT                               ___________________   _______________
Expiry Date: 1200 PT                                      Quality Control           Date
</TABLE>

                             QUALITY CONTROL RESULTS

<TABLE>
<CAPTION>
              TESTS                      RESULTS            SPECIFICATIONS         DOCUMENT
              -----                      -------            --------------         --------
<S>                                <C>                  <C>                      <C>
Visual Inspection                  Conform:                Clear, colourless      ACR-16-003
                                   [ ] Y   [ ] N         solution, essentially
                                                        free of foreign matter
                                                            visible to the
                                                             unaided eye.

pH                                                             8.2 - 9.2          ACR-16-006

Activity Concentration**                       mCi/mL     2.25 - 2.75 mCi/mL      ACR-16-005

Total Activity**                                  mCi        4.5 - 5.5 mCi        PCR-16-030

Identity (iodofiltic acid I-123)                           Rr* = 0.95 - 1.05      ACR-16-024A

Radionuclidic Identity                            keV        157 - 161 keV

Radionuclidic Purity**                        % I-123     > or = 99.8% I-123      ACR-16-007

Radiochemical Purity                 % as iodofiltic       > or = 95% as          ACR-16-024B
                                       acid I-123        iodofiltic acid I-123

         CHEMICAL PURITY

BMIPP                                           mg/mL    0.225 to 0.275 mg/mL     ACR-16-024A

UDCA                                            mg/mL     3.15 to 3.85 mg/mL

Endotoxin Limit Test (LAL)                      EU/mL      < or = 17.5 EU/mL      ACR-10-003
Sterility                          Test initiated on     Meet USP requirements    ACR-78-001
                                   day of Manufacture
                                   by: ______________

Autocalve Results                  Reviewed by: _____     Autoclave printout      PCR-73-001
                                                            reviewed by QC
</TABLE>

*    Rr is the retention time of the product (iodofiltic acid I-123) divided by
     the retention time of the reference standard (non-radioactive iodofiltic
     acid I-123)

**   At calibration time, 1500 h PT, one day after date of manufacture.

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 12 of 28

<PAGE>

                                APPENDIX 2 - CONT.
                             PRODUCT RELEASE FORMS

Issue No.: 1                       Product Release Form              PRF-16-001A
Effective: 2005.09.14           for iodofiltic acid I-123            Page 2 of 2

<TABLE>
<CAPTION>
                    DOCUMENTS REQUIRED FOR BATCH RELEASE                        X
----------------------------------------------------------------------------   ---
<S>                                                                            <C>
SOP-16-301      Sodium Iodide-123 (I-123) Radiochemical for iodofiltic acid
                I-123 Production (Certificate of Analysis)

SOP-16-300      Sodium Iodide-123 (I-123) Radiochemical for iodofiltic acid
                I-123 Production (Certificate of Compliance)

PCR-16-001      Production of iodofiltic acid I-123

PCR-16-030      Capintee Calibration and Total Activity Measurement of
                Dispensed Vials of iodofiltic acid I-123

ACR-16-005      Activity Concentration of iodofiltic acid I-123

ACR-16-007      High Resolution Gamma Measurement of iodofiltic acid I-123
                Radionuclidic Identity and Purity

ACR-16-006      pH Determination of iodofiltic acid I-123

ACR-16-011      Preparation of Mobile Phase Solvents for High Performance
                Liquid (Illegible) (HPLC) Quality Control Assay of iodofiltic
                acid I-123

ACR-16-012      iodofiltic acid I-123 Quality Control Assay HPLC System
                Preparation

ACR-16-013      iodofiltic acid I-123 Quality Control HPLC System Clean-up
                and Storage

ACR-16-010      Reconciliation of Dispensed Vials of iodofiltic acid I-123

ACR-16-003      Visual Inspection of Dispensed Vials of iodofiltic acid
                I-123

PCR-73-001      Operation of Radiopharmaceutical Autoclave (Illegible)

PCR-16-017      Preparation of iodofiltic acid I-123 Component Kits

PCR-16-018      Printing and Control of Vial Labels for iodofiltic acid
                I-123

PCR-16-019      Printing and Control of Outer Lead Pot Labels for iodofiltic
                acid I-123

PCR-16-032      iodofiltic acid I-123 Purification HPLC System Preparation

PCR-16-033      Preparation of Mobile Phase Solvents for High Performance
                Liquid Chromatography (HPLC) Purification of iodofiltic
                acid I-123

PCR-16-011      Dispensing of iodofiltic acid I-123

ACR-16-024A     High Performance Liquid Chromatography (HPLC) Quality Control
                Assay of iodofiltic acid I-123

ACR-16-024B     High Performance Liquid Chromatography (HPLC) Quality Control
                Assay of iodofiltic acid I-123

PCR-16-034      iodofiltic acid I-123 Purification HPLC System Clean-up and
                Storage

PCR-16-043      iodofiltic acid I-123 Pre-process Preparation

PCR-16-101A     Nonviable Environmental Monitoring for iodofiltic acid I-123

ACR-10-003      Bacterial Endotoxin Test (LAL Test)

SOP-70-002      Deviation (as required): DN-155-______________________

SOP-80-001      Positive Recall (as required), Ctrl No.: _____________
</TABLE>

Prepared by: Victor Ong                                Date: 2005.07.28

Revised by: /s/ Illegible                              Date: (Illegible)
            ----------------------------------------

Approved by: /s/ Illegible                             Date: (Illegible)
             ---------------------------------------
             Quality

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 13 of 28

<PAGE>

                                APPENDIX 2-CONT.
                             PRODUCT RELEASE FORMS

                                                     Each page of this document
                                                     has been checked against
                                                     the transfer copy of
                                                     accuracy.

                                                     Verified __________________

                                                     Date ______________________

                                   MDS NORDION
                              VANCOUVER OPERATIONS
                              PRODUCT RELEASE FORM

Issue No.: 1      Product Release Form For iodofiltic Acid I-123     PRF-16-001B
Effective: 2005.09.14                                                Page 1 Of 1

<TABLE>
<CAPTION>
         DOCUMENTS REQUIRED FOR COMPLETE BATCH RECORD (POST RELEASE)          X
---------------------------------------------------------------------------- ---
<S>                                                                          <C>
PCR-16-039      Cleaning of the Hamilton Syringe Pump

PCR-16-100      Viable Environmental Monitoring for iodofiltic acid I-123

ACR-78-001      Sterility Testing of Radiopharmaceutical Products

SOP-80-011      OOSI (as required): Ctrl No.: ______________________

PCR-70-005 A/B  NCMR (as required): Ctrl No.: ______________________

SOP-80-008      PAFI (as required): PAFI-155-_______________________
</TABLE>

              QUALITY CONTROL POST RELEASE - MICROBIOLOGICAL TESTS

<TABLE>
<CAPTION>
TESTS              RESULTS                SPECIFICATIONS               DOCUMENT
-----              -------   --------------------------------------   ----------
<S>                <C>       <C>                                      <C>
Biological                   -    Negative growth of the exposed
Indicator                         ampoule                             PCN-73-001
for Autoclave
                             -    Positive growth of the unexposed
                                  positive control                    (#0 - ___)

Sterility                                 Negative growth             STM-78-001

                                                                      (#0 - ___)

Bacteriostasis/                           Positive growth             STM-78-001
Fungistasis
                                                                      (#0 - ___)
</TABLE>

Approved by:                                           Date:
             ---------------------------------------         -------------------
             Quality Control

Prepared by: Victor Ong                                Date: 2005.07.25

Revised by: /s/ Illegible                              Date: (Illegible)
            ----------------------------------------

Approved by: /s/ Illegible                             Date: (Illegible)
             ---------------------------------------
             Quality
________________________________________________________________________________
Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 14 of 28

<PAGE>

                                   APPENDIX 3
                              STABILITY PROCEDURES

                                  MDS NORDION.
                              VANCOUVER OPERATIONS
                              STANDARD TEST METHOD

Issue No.: 0    Product Release Form For Iodofiltic Acid I-123        STM-16-002
Effective: 2005.O8.25                                                Page 1 of 6

1.   PURPOSE

     1.1  The purpose of the stability protocol is to validate the assigned
          shelf-life of the iodofiltic acid I-123 under recommended storage
          conditions (20-25 degrees C).

2.   POLICY

     2.1  The information provided by the stability protocol remains valid only
          as long as the source and the standard of the raw materials, the
          manufacturing process and equipment, and the standard for the drug
          product and its packaging components remain constant. Any significant
          change in any of these factors should lead to a review of the
          stability study.

     2.2  The stability of the product is revalidated after any significant
          changes in formulation, manufacturing procedures or packaging
          materials that may affect the shelf life of the product.

     2.3  Deviations from this STM will be immediately brought to the attention
          of the Quality Director or designate, and the protocol SOP-70-002,
          Deviations from Approved Procedures will be followed.

     2.4  Any action arising as a result of deviations will be recorded.

     2.5  This STM is to be followed for the first three validation runs and on
          one representative production lot per year.

3.   RESPONSIBILITIES

     3.1  The QC technician shall rigidly adhere to this protocol, to promptly
          record all dain and to report any and all deviations.

     3.2  The QC technician shall promptly report all results falling to meet
          specifications to the Director, Quality, Safety, and Regulatory
          Affairs or designate. Such actions shall be recorded.

     3.3  The QC department shall compile and maintain ACR-46-002 and all
          Quality Records relevant to the Stability Validation.

4.   STABILITY STUDIES

     4.1  Stability studies on iodofiltic acid I-123 final product are to be
          done at the time of manufacture (the normal time of QC analyses for
          final product release), on the calibration date and on the day after
          expiry date.

          Ensure Expiry Date study is performed on or after 1200 h PT on the day
          of expiry so as to validate the entire shelf life.

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 15 of 28
<PAGE>

                               APPENDIX 3 - CONT.
                              STABILITY PROCEDURES

Issue No.: 0      Stability Protocol for Iodofiltic acid I-123        STM-16-002
Effective: 2005.08.25                                                Page 2 of 6

     4.2  In order to represent the "worst case" scenario, vials of Iodofiltic
          acid I-123 are placed upside down at 20 degrees - 25 degrees C to
          maximize the time the teflon lined rubber stopper is in contact with
          the production solution, for the day after manufacture and two days
          after manufacture tests.

     4.3  THE FOLLOWING PARAMETERS ARE MONITORED:

<TABLE>
<CAPTION>
               PARAMETER                    DOCUMENT
               ---------                  -----------
<S>                                       <C>
4.3.1  Visual Inspection                  ACR-46-003
4.3.2  pH                                 ACR-46-006
4.3.3  Activity Concentration             ACR-46-005
4.3.4  Total Activity                     PCR-46-030
4.3.5  Identity (Iodofiltic acid I-123)   ACR-46-024A
4.3.6  Radionuclidic Identity             ACR-46-007
4.3.7  Radionuclidic Purity               ACR-46-007
4.3.8  Radiochemical Purity               ACR-46-024B
4.3.9  Chemical Purity
       4.3.9.1 BMIPP                      ACR-46-024A
       4.3.9.2 UDCA                       ACR-46-024A
       4.3.9.3 Ethanol                    ACR-46-031
4.3.10 Endotoxin Limit Test(LAL)          ACR-10-003
4.3.11 Sterility                          ACR-78-001

</TABLE>

     4.4  IODOFILTIC ACID I-123 SAMPLE SIZE

          4.4.1 Visual Inspection

               4.4.1.1 All dispensed vials of iodofiltic acid I-123 are visually
                    inspected for particles, labels and container closure system
                    integrity on the day of manufacture prior to final product
                    release.

                    Note: In a regular manufacturing run, one vial for Endotoxin
                    test and one vial for HPLC are taken prior to visual
                    inspection due to time constraints.

               4.4.1.2 Vials of iodofiltic acid I-123 for QC samples are
                    visually inspected at subsequent stability time points.

          4.4.2 Chemical tests for the First Three Validation Lots

               Each set of chemical tests requires two vials (one for HPLC and
               one for other chemical tests) which is based on the above test
               parameters in section 4.3.1 to 4.3.9.2.

Intercompany Quality Agreement                                             Rev.0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 16 of 28

<PAGE>

                                APPENDIX 3 - CONT.
                              STABILITY PROCEDURES

Issue No.: 0      Stability Protocol for iodofiltic acid I-123        STM-16-002
Effective: 2005.08.25                                                Page 3 of 6

               4.4.2.1 On the day of iodofiltic acid I-123 manufacture, collect
                    six vials, two vials from the beginning, two vials from the
                    middle and two vials from the end of the iodofiltic acid
                    I-123 dispensed vials.

                    4.4.2.1.1 With reference to Section 4.3.1 to 4.3.9.2,
                         perform HPLC and other chemical tests on each of the
                         three vials collected (one from the beginning, one from
                         the middle, and one from the end) of the dispensed
                         vial.

                    4.4.2.1.2 Report each set of test results (HPLC and chemical
                         tests) in VCR-16-009 for manufacturing process
                         validation of iodofiltic acid I-123.

                    4.4.2.1.3 Report one set of test results from Section
                         4.4.2.1.2 (HPLC and chemical tests) in ACR-46-002 in
                         the column "on the day of manufacture"

               4.4.2.2 On the day of iodofiltic acid I-123 manufacture, five
                    additional iodofiltic acid I-123 vials are to be collected
                    randomly and placed upside down at 20-25 degrees C.

                    4.4.2.2.1 On the day of calibration date of iodofiltic acid
                         I-123 product, use one upside down vial for HPLC
                         analysis and use one upside down vial for chemical
                         tests (Section 4.3.1 to 4.3.9.2). Report the test
                         results in ACR-46-002.

                    4.4.2.2.2 Similarly on the day of expiry date, use one
                         upside down vial for HPLC analysis and one upside down
                         vial for chemical tests. Report the test results in
                         ACR-46-002.

                    4.4.2.2.3 Ethanol content is analyzed at post expiry date
                         and the test result is recorded in the post expiry date
                         column on VCR-46-009 Manufacturing Process Validation
                         of Iodofiltic acid I-123 and ACR-46-002 Stability
                         Protocol for iodofiltic acid I-123.

          4.4.3 Chemical Tests for Annual Product Stability Lot

               Each set of chemical tests requires two vials (one for HPLC and
               one for other chemical tests) which are based on section 4.3.1 to
               4.3.9.2.

               4.4.3.1 On the day of iodofiltic acid I-123 manufacture, collect
                    two random vials from Production.

                    4.4.3.1.1 Perform HPLC analysis on one vial and other
                         chemical tests on the second vial as described in
                         Section 4.3.1 to 4.3.9.

                    4.4.3.1.2 Report the test results in ACR-46-002 in the
                         column "On the Day of Manufacture".

               4.4.3.2 On the day of manufacture, five additional iodofiltic
                    acid I-123 vials are to be collected randomly and placed
                    upside down at 20-25 degrees C.

Intercompany Quality Agreement                                             Rev.0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 17 of 28

<PAGE>

                                APPENDIX 3 -CONT.
                              STABILITY PROCEDURES

Issue No.: 0      Stability Protocol for iodofiltic acid I-123        STM-16-002
Effective: 2005.08.25                                                Page 4 of 6

                    4.4.3.2.1 On the day of calibration date of iodofiltic acid
                         I-123 product, use one upside down vial for HPLC
                         analysis and use one upside down vial for other
                         chemical tests (Section 4.3.1 to 4.3.9.2). Report the
                         test results in ACR-46-002.

                    4.4.3.2.2 Similarly on the day of expiry date, use one
                         upside down vial for HPLC and use one upside down vial
                         for other chemical tests (section 4.3.1 to 4.3.9.2).
                         Report the test results in ACR-46-002.

                    4.4.3.2.3 Perform Ethanol content analysis on post
                         iodofiltic acid I-123 expiry date.

                    4.4.3.2.4 Report test results in ACR-46-002 in the column
                         "Post Expiry Date".

          4.4.4 Microbiological Tests (Sterility and Endotoxin) for the first
               Three Validation Lots and for Annual Product Stability Lot

               4.4.4.1 On the day of iodofiltic acid I-123 manufacture, five
                    vials are collected, with three vials being collected in a
                    manner similar to Section 4.4.2.1 (i.e., one from the
                    beginning, one from the middle, and one from the end). These
                    are pooled with a fourth vial (selected randomly) and all
                    four are used for sterility testing. One extra vial is
                    collected randomly for Endotoxin testing.

               4.4.4.2 On the day of manufacture, ten additional iodofiltic acid
                    I-123 vials are collected randomly and placed upside down at
                    20-25 degrees C

                    4.4.4.2.1 On the day of calibration date of iodofiltic acid
                         I-123 product, four upside down vials are used for
                         sterility test. One vial is tested for Endotoxin.

                    4.4.4.2.2 On the day of expiry date of the iodofiltic acid
                         I-123 product, four remaining upside down vials are
                         used for sterility test. One vial is tested for
                         Endotoxin.

          4.4.5 Testing Schedule

               4.4.5.1 ACR-46-002 shows the testing schedule for the various QC
                    analysis at the different stability time points. Report all
                    the test results in the ACR.

Intercompany Quality Agreement                                             Rev.0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 18 of 28
<PAGE>

                               APPENDIX 3 - CONT.
                              STABILITY PROCEDURES

Issue No.: 0           Stability Protocol for iodofiltic acid I-123   STM-16-002
Effective: 2005.08.25                                                Page 5 of 6

5.   CRITERIA FOR ACCEPTABLE LEVELS OF STABILITY

<TABLE>
<CAPTION>
                                 CONDITION MAINTAINED THROUGHOUT THE
TYPE OF STABILITY                  SHELF-LIFE OF THE DRUG PRODUCT
-----------------   ------------------------------------------------------------
<S>                 <C>
     Chemical       Each active ingredient retains its chemical integrity and
                    labelled potency, within the specified limits.

     Physical       The original physical properties, including appearance,
                    uniformity, and solubility are retained.

 Microbiological    The product meets the specified limits for endotoxin and
                    sterility at the beginning and at the end of its assigned
                    shelf life.
</TABLE>

6.   DOCUMENTATION

<TABLE>
<CAPTION>
                               Document
      ---------------------------------------------------------
<S>   <C>          <C>
6.1   ACR-46-002   Stability Protocol for iodofiltic acid I-123
</TABLE>

7.   APPENDICES

     7.1  Appendix I: Sampling Plan on Dispensed Vials for Manufacturing Process
          Validation of iodofiltic acid I-123

     7.2  Appendix II: Sampling Plan on Dispensed Vials for Annual Stability
          Study of iodofiltic acid I-123

Prepared by: /s/ Illegible                              Date: (Illegible)
             ----------------------------------------

Approved by: /s/ Illegible                              Date: (Illegible)
             ----------------------------------------
             Quality

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 19 of 28

<PAGE>

                               APPENDIX 3 - CONT.
                              STABILITY PROCEDURES

Issue No.: 0           Stability Protocol for Iodofiltic acid I-123   STM-16-002
Effective: 2005.08.25                                                Page 6 of 6

                                   Appendix I

           Sampling Plan on Dispensed Vials for Manufacturing Process
                       Validation of iodofiltic acid I-123

<TABLE>
<CAPTION>
                       On the day of          On              On            Post
                        manufacture    Calibration Date   Expiry Date   Expiry Date
                       -------------   ----------------   -----------   -----------
<S>                    <C>   <C>       <C>       <C>      <C>    <C>    <C>    <C>
   HPLC Analysis        3     B,M,E         1*    R         1*    R
  Chemical tests        3     B,M,E         1*    R         1*    R
 Ethanol Analysis                                                         1*    R
Endotoxin test (LAL)    1       R           1*    R         1*    R
   Sterility test       4    B,M,E,R        4*    R         4*    R
</TABLE>

Total Vials Required: 26

                                   Appendix II

    Sampling Plan on Dispensed Vials for Annual Stability Study of iodofiltic
                                   acid I-123

<TABLE>
<CAPTION>
                       On the day of          On              On            Post
                        manufacture    Calibration Date   Expiry Date   Expiry Date
                       -------------   ----------------   -----------   -----------
<S>                    <C>   <C>       <C>       <C>      <C>    <C>    <C>   <C>
   HPLC Analysis        1       R           1*    R         1*    R
  Chemical tests        1       R           1*    R         1*    R
 Ethanol Analysis                                                         1*    R
Endotoxin test (LAL)    1       R           1*    R         1*    R
   Sterility test       4    B,M,E,R        4*    R         4*    R
</TABLE>

Total vials required: 22

B = Beginning of dispensed vials

M = Middle of the dispensed vials

E = End of the dispensed vials

R = Random dispensed vials

*    Vials are collected on the day of manufacture and are store upside down at
     20-25 degrees C prior to performing the required tests.

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 20 of 28

<PAGE>

                               APPENDIX 3 - CONT.
                              STABILITY PROCEDURES

                                                  Each page of this document
                                                  has been checked against the
                                                  master copy for accuracy

                                                  Verified

                                                  Date

                                  MDS NORDION
                              VANCOUVER OPERATIONS
                              STANDARD TEST METHOD

Issue No.: 0       Stability Protocol for iodofiltic acid I-123       ACR-16-002
Effective: 2005.08.25                                                Page 1 of 2

               IODOFILTIC ACID I-123                         LOT NUMBER
              PRODUCT STABILITY STUDY                   BMI - _____________

Date of Manufacture __________________________   Date of Expiry ________________

     Conditions:  iodofiltic acid I-123 vials were stored upside down at 20-25
                  degrees C. The product solution was in contact with the teflon
                  lined rubber slippers.

<TABLE>
<CAPTION>
                                                            Day of     Calibration                     Post
                                     Specification       Manufacture       Date      Expiry Date   Expiry Date
                                 ---------------------   -----------   -----------   -----------   -----------
<S>                              <C>                     <C>           <C>           <C>           <C>
Visual Inspection                   Clear colourless
                                 solution, essentially
                                    free of foreign
                                 matter visible to the
                                      unaided eye.

pH                                      8.2-9.2

Activity Concentration*             2.25-2.75 mCi/mL

Total Activity*                       4.5-5.5 mCi

Identity Iodofiltic acid I-123        Rr=0.95-1.05

Radionuclidic Identity                157-161 keV

Radionuclidic Purity*              > or = 99.8% I-123

Radiochemical Purity                 > or = 95% as
                                 iodofiltic acid I-123

        Chemical Purity

BMIPP                               0.225-0.275mg/mL

UDCA                                3.15-3.85 mg/mL

Ethanol                                2-10% v/v

Endotoxin Limit Test (LAL)         < or = 17.5 EU/mL

Sterility                              Meets USP
                                      requirements
</TABLE>

*    Term of (Illegible)

*    (Illegible)

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 21 of 28

<PAGE>

                               APPENDIX 3 - CONT.
                              STABILITY PROCEDURES

Issue No.: 0       Stability Protocol for iodofiltic acid I-123       ACR-16-002
Effective: 2005.08.25                                                Page 2 of 2

Comments

________________________________________________________________________________

________________________________________________________________________________

________________________________________________________________________________

________________________________________________________________________________

________________________________________________________________________________

________________________________________________________________________________

________________________________________________________________________________

Compiled by:                                            Date:
             ----------------------------------------         ------------------

Approved by:                                            Date:
             ----------------------------------------         ------------------

Prepared by: /s/ Illegible                              Date: 2005/08/22
             ----------------------------------------

Approved by: /s/ Illegible                              Date: 2005/8/24
             ----------------------------------------
             Quality

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 22 of 28

<PAGE>

                                   APPENDIX 4
                                 QUALITY RECORDS

                                   MDS NORDION
                              VANCOUVER OPERATIONS
                          STANDARD OPERATING PROCEDURE

Issue No.: 6                     Quality Records                      SOP-80-005
Effective: 2003.12.02                                               Page: 1 of 5

1    INTRODUCTION

     1.1  PURPOSE

          1.1.1 This procedure identifies Nordion's Vancouver Operations Quality
               Records and describes their collection, indexing, access, filing,
               storage, maintenance and disposition requirements.

     1.2  POLICY

          1.2.1 This procedure applies to Quality Records at Nordion's Vancouver
               Operations as they pertain to ISO 9001:2000.

          1.2.2 Procedures describing the upkeep of the records systems are
               current and effective.

          1.2.3 Records are stored under conditions that allow rapid retrieval,
               ensure safekeeping and protect proprietary information.

          1.2.4 Records are reviewed and approved by the designated personnel.

          1.2.5 All Quality Records shall be legible and identifiable to the
               product involved.

     1.3  RESPONSIBILITIES

          1.3.1 Management shall determine record requirements and ensure that
               adequate systems for records are implemented and maintained.

          1.3.2 Each functional group shall assure a Quality Records
               Responsibility and Maintenance Form (QRRMF, Appendix I) is
               completed.

          1.3.3 Individuals identified on the QRRMF shall manage the record for
               its entire stipulated life cycle.

          1.3.4 The Quality Director or designate shall handle, maintain and
               dispose of off-site records as per SOP-80-015 Control of Records
               Stored Off-Site.

          1.3.5 The Quality Department shall maintain Internal storage, truck
               retention times and issue disposition instructions, where
               applicable.

          1.3.6 Onsite records retrieved from their storage area shall require
               the approval of the Director, Quality, Safety, and Regulatory
               Affairs or designate. A logbook shall be maintained to record
               such activities.

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 23 of 28

<PAGE>

                               APPENDIX 4 - CONT.
                                 QUALITY RECORDS

Issue No.: 6                     Quality Records                      SOP-80-005
Effective: 2003.12.02                                               Page: 2 of 5

2    PREPARATION

     2.1  DOCUMENTS

          2.1.1 All documents pertaining to the Quality Records described herein
               are identified in the individual QRRMF.

          2.1.2 Quality Manual

     2.2  APPENDICES

          2.1.1 Appendix I: Quality Records Responsibility and Maintenance Form
               (QRRMF).

          2.1.2 Appendix II: Description of the Elements on the QRRMF.

3    DEFINITIONS

     3.1  QUALITY RECORDS: For each Quality Record identified, a Quality Record
          Responsibility and Maintenance Form (Appendix I) will be issued
          describing responsibility, location and retention periods.

     3.2  SUPPLIER RECORDS: Where contractual agreements have been for a
          supplier to maintain records, details are indicated in the Purchase
          Order or contract. Access by Nordion to these records is part of the
          terms and conditions.

     3.3  SECURITY: Quality records are maintained in locked rooms or cabinets
          located in a suitable environment to minimize deterioration or damage
          to the records. Usually the storage areas are sprinklered or suitable
          fire resistance containment is used. Record release is strictly
          controlled and limited to authorized Nordion personnel, customers, or
          regulatory bodies. Copies may be sent or used as necessary. See
          Section 1.3.4 for more information on the security of offsite quality
          records.

     3.4  MAINTENANCE AND CHANGES TO RECORDS: Records are identified, indexed
          and filed for easy retrieval. Each document is filed under a unique
          code and records are maintained of revisions. Records of all revisions
          remain as records for reference.

     3.5  RECORD RETENTION PERIODS: Each record or group of records has a
          retention period. This period is established in consultation with the
          cognizant line management and the Director, Quality, Safety and
          Regulatory Affairs. Where a retention period is indicated as "minimum
          one year", this implies that records from the previous calendar year
          and year to date are maintained prior to the disposition being
          considered. A "minimum of five years" Implies that records from the
          previous five years and year to date are maintained prior to
          disposition being considered. Onsite Retention Periods and Offsite
          Retention Periods are recorded on the Quality Records Responsibility
          and Maintenance Forms (QRRMF) (see Appendix I).

     3.6  ALL RECORDS MUST BE LEGIBLE. This is to include no pencil entries and
          proper reproduction equipment so as to provide clear copies.

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 24 of 28

<PAGE>

                               APPENDIX 4 - CONT.
                                 QUALITY RECORDS

Issue No.: 6                     Quality Records                      SOP-80-005
Effective: 2003.12.02                                               Page: 3 of 5

     3.7  All records are to be clearly identifiable to the product involved by
          proper indication on each record of specific identifiers.

4    PROCEDURE

     4.1  Upon identification of a Quality Record, the originator shall use the
          format as provided for QRRMF (Appendix I). The originator shall
          complete the following actions and obtained approval from their
          respective line manager.

          Section 1. Quality Record
          Section 2  Reference Document
          Section 3  Responsible Person(s) Job Title
          Section 4  Location of On-Site Storage
          Section 5  Location of Off-Site Storage
          Section 6  Method for Indexing and Storage
          Section 9  Media

     4.2  The line manager in consultation with the Manager, Quality, Safety,
          and Regulatory Affairs shall complete the following sections:

          Section 7  On-Site Retention Time
          Section 8  Off-Site Retention Time
          Section 10 Disposition

     4.3  Upon receipt of a QRRMF, the Document Coordinator shall create a Data
          Control Sheet and update DCS-76-001 QRRMF Master list.

     4.4  In order to ensure that QRRMF are up-to-date, such documents shall be
          included as part of the Annual Review of documents as per SOP-70-017
          Annual Review of Control Documents.

                                Document Approval

Prepared by: Michael Chin                             Date: 1997.06.23

Revised by: /s/ Illegible                             Date: (Illegible)
            ---------------------------------------

Approved by: /s/ Illegible                            Date: (Illegible)
             --------------------------------------
             Quality

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 25 of 28

<PAGE>

                               APPENDIX 4 - CONT.
                                 QUALITY RECORDS

Issue No.: 6                     Quality Records                      SOP-80-005
Effective: 2003.12.02                                               Page: 4 of 5

        APPENDIX I - QUALITY RECORDS RESPONSIBILITY AND MAINTENANCE FORM

<TABLE>
<S>                                  <C>
1. Quality Record

2. Reference Document

3. Responsible Person(s) Job Title

4. Location of On-Site Storage

5. Location of Off-Site Storage

6. Method for Indexing and Storage

7. On-Site Retention Time

8. Off-Site Retention Time

9. Media:

10 Disposition
</TABLE>

Prepared by:                                           Date:
             ---------------------------------------         -------------------

Approved by:                                           Date:
             ---------------------------------------         -------------------
             Line Manager

Approved by:                                           Date:
             ---------------------------------------         -------------------
             Manager, Quality, Safety, and
             Regulatory Affairs

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 26 of 28

<PAGE>

                               APPENDIX 4 - CONT.
                                 QUALITY RECORDS

Issue No.: 6                     Quality Records                      SOP-80-005
Effective: 2003.12.02                                               Page: 5 of 5

                        APPENDIX II - ELEMENT DESCRIPTION

<TABLE>
<S>                                  <C>
1. Quality Record                    The title of the Quality Record.

2. Reference Document                Document or procedure describing the
                                     Quality Record.

3. Responsible Person(s) Job Title   Title of designated responsible
                                     individual(s).

4. Location of On-Site Storage       A general description of the physical area
                                     within the Vancouver facility in which the
                                     records are stored.

5. Location of Off-Site Storage      A general description of the physical area
                                     off the Vancouver premises in which the
                                     records are stored.

6. Method for Indexing and Storage   This describes how the records are indexed
                                     and store, i.e., by part number, date, P.O.
                                     number, unique identifiers, etc.

7. On-Site Retention Time            This minimum duration for on-side record
                                     retention.

8. Off-Site Retention Time           The minimum duration for off-site record
                                     retention.

9. Media:                            Describes the physical record type, i.e.,
                                     paper, microfilm, computer records, etc.

10 Disposition                       Means of disposing of records.
</TABLE>

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 27 of 28

<PAGE>

                               APPENDIX 4 - CONT.
                                 QUALITY RECORDS

                                  MDS NORDION
                              VANCOUVER OPERATIONS
                               DATA CONTROL SHEET

Issue No.: 3        QRRMF: Batch Records (Radiopharmaceuticals)       DCS-76-004
Effective: 2005.07.18                                               Page: 1 of 1

               QUALITY RECORDS RESPONSIBILITY AND MAINTENANCE FORM

<TABLE>
<S>                                  <C>
1. Quality Record                    Batch Records (Radiopharmaceuticals)

2. Reference Document                Product SOPs, PCRs, STMs, ACRs, PRFs

3. Responsible Person(s) Job Title   QA Designate

4. Location of On-Site Storage       QC Administration Office or QA Records Room

5. Location of Off-Site Storage      Iron Mountain

6. Method for Indexing and Storage   By product and sequentially by batch

7. On-Site Retention Time            Minimum 1 month, except rejected batches,
                                     which are kept on-site permanently

8. Off-Site Retention Time           Permanent

9. Media:                            Paper

10 Disposition                       N/A
</TABLE>

Prepared by: Michael Chin                             Date: 2000.03.23

Revised by: /s/ Illegible                             Date: (Illegible)
            ---------------------------------------

Approved by: /s/ Illegible                            Date: (Illegible)
             --------------------------------------
             Quality

Intercompany Quality Agreement                                            Rev. 0
MDS Nordion and Molecular Insight Pharmaceuticals, Inc.            Page 28 of 28
<PAGE>

                                       72

                                   SCHEDULE G

        SPECIFICATIONS FOR PRECURSOR, REFERENCE STANDARDS AND EXCIPIENTS

                       PRECURSOR AND REFERENCE STANDARDS:

                                   MDS NORDION
                              VANCOUVER OPERATIONS
                           RAW MATERIALS SPECIFICATION

Issue No.: 0         15-(p-Iodophenyl)-3-methylpentadecanoic          SPE-46-007
Effective: 2005.07.11             Acid (BMIPP)                       Page 1 of 1

<TABLE>
<S>                  <C>
PRODUCT              : 15-(p-Iodophenyl)-3-methylpentadecanoic Acid (BMIPP)

DESCRIPTION          : White crystalline powder

VISUAL INSPECTION    : Each lot or every shipment shall be visually inspected
                       for appropriate labelling and contents, Materials,
                       packaging, product and package integrity or damage.
                       Materials should be essentially free of foreign matter
                       visible to the unaided eye.

IDENTIFICATION       : Melting range 53.5 to 55.0 degrees C

SUPPLIER             : TCI America

CATALOGUE NUMBER     : Z3398

SIZE*                : Variable

STORAGE CONDITIONS   : Containers shall be identified with proper distinct
                       labelling for each lot and each shipment received. All
                       containers shall be stored off the floor at all times in
                       a manner to prevent contamination. Refer to cGMP 211.80.
                       Material shall be stored at 2 TO 8 degrees C in the dark.

CERTIFICATE          : Certificate of Analysis

EXPIRY DATE          : One year After receipt.
</TABLE>

*    Based on Manufacturer's claim

Prepared by: /s/ Illegible                             Date: (Illegible)
             ---------------------------------------

Approved by: /s/ Illegible                             Date: 2005/7/8
             ---------------------------------------
             Quality

                               UNCONTROLLED COPY

<PAGE>

                                       73

                               SCHEDULE G (CONT.)

                                  EXCIPIENTS:

                                   MDS NORDION
                              VANCOUVER OPERATIONS
                           RAW MATERIALS SPECIFICATION

Issue No.: 0              Ursodeoxycholic Acid (Ursodiol or UDCA)     SPE-46-008
Effective: 2005.07.11                                                Page 1 of 1

<TABLE>
<S>                  <C>
PRODUCT              : Ursodeoxycholic Acid (Ursodiol OR UDCA)

DESCRIPTION          : White crystalline powder

VISUAL INSPECTION    : Each lot of every shipment shall be visually inspected
                       for appropriate labelling and contents, materials,
                       packaging, product and package integrity or damage.
                       Materials should be essentially free of foreign matter
                       visible to the unaided eye.

IDENTIFICATION       : Melting range between 200 to 2O5 degrees C

GRADE*               : Eur. Ph.

SUPPLIER             : Diapharma Francis, Erregierre S.p.A.

CATALOGUE NUMBER     : Material Code 500346, Code 110

SIZE*                : Variable

STORAGE CONDITIONS   : Containers shall be identified with proper distinct
                       labelling for each lot and each shipment received. All
                       containers shall be stored off the floor at all times in
                       a manner to prevent contamination. Refer to cGMP 211.80.
                       Material shall be stored at 2 to 8 degrees C in the dark.

CERTIFICATE          : Certificate of Analysis

EXPIRY DATE          : Manufacturer's expiry date.
</TABLE>

*    Based On manufacturer's claim

Prepared by: /s/ Illegible                             Date: (Illegible)
             ---------------------------------------

Approved by: /s/ Illegible                             Date: 2005/7/8
             ---------------------------------------
                             Quality<PAGE>

                                                                   EXHIBIT 10.24

THIS AGREEMENT made in duplicate as of the 22 day of March, 2006,

BETWEEN:

           MDS NORDION, a division of MDS (Canada) Inc. a corporation
           incorporated under the laws of Canada having a place of business at
           447 March Road, Kanata, Ontario, Canada, K2K 1X8

                                                                     ("Nordion")

AND:

           Molecular Insight Pharmaceuticals, Inc. a corporation incorporated
           under the laws of the Commonwealth of Massachusetts having place of
           business at 160 Second Street, Cambridge Massachusetts, 02142, USA

                                                                         ("MIP")

WHEREAS:

I    MIP is the owner of certain data, information and technology related to a
     radiotherapeutic known as Ultratrace I-131 MIBG ("I-131 MIBG") and
     processes for making the same, which is under development for use in the
     treatment of neuroendocrine tumours;

II   Nordion has expertise in the development of radiopharmaceutical processes;

III  MIP desires that Nordion carry out a feasibility and development program to
     establish a suitable dose configuration and batch process to support
     clinical development of I-131 MIBG.

<PAGE>

                                       2

NOW THEREFORE in consideration of the mutual covenants and agreements herein
contained, and subject to the terms and conditions hereinafter set out, the
parties hereto agree as follows:

1.   SCOPE AND OBJECT

     The scope and object of this Agreement is to carry out a feasibility and
     development program to establish a suitable dose configuration and batch
     process to support clinical development of I-131 MIBG, in accordance with
     the development responsibilities and obligations attributed to each of the
     parties as set out in Schedule A (the "Project"), which shall serve as a
     guideline in carrying out the Project.

2.   TERM

     The Project and this Agreement shall be deemed to have commenced as of the
     date first written above ("Effective Date") and shall terminate upon the
     earlier of (i) completion of the Project or (ii) one year after the
     Effective Date. The parties estimate that the Project will be completed in
     a period of five (5) to six (6) months after the Effective Date. If either
     party fails to perform any material obligation under this Agreement, then
     the non defaulting party may terminate this Agreement upon thirty (30) days
     prior written notice to the defaulting party, unless the defaulting party
     remedies the default within the given notice period. The non-defaulting
     party may pursue any and all remedies it may have in connection with such
     default and termination.

3.   DEVELOPMENT ACTIVITIES

     Nordion and MIP shall use commercially reasonable efforts to carry out the
     respective obligations described and attributed in Schedule A, it being
     understood that some development activities may be delayed to the extent
     that such activity is based on the performance of or the provision of data,
     information or technology by the other party. Nordion will notify MIP in
     writing as soon as reasonably possible of any risk or inability to achieve
     the deliverables under this

<PAGE>
                                       3

     Agreement, either in whole in part, or by the time set forth on Schedule A.
     MIP shall, at no cost to Nordion, provide MIBG precursor and reference
     standard in sufficient quantities to carry out the Project.

     The parties acknowledge and agree that Schedule A may be amended during the
     course of this Project in order to accommodate unforeseen events and
     results. All such changes to Schedule A shall be made by written agreement
     of the parties. If any change to Schedule A materially impacts the scope of
     work to be provided by Nordion, Nordion will provide a written estimate of
     the increase in hours, at the rate of ** which must be approved
     in advance by Molecular Insight Pharmaceuticals. No work on such scope
     change shall be carried out by Nordion prior to Nordion's receipt of
     Molecular Insight Pharmaceuticals' written approval of such change.

4.   PAYMENTS

     In consideration of Nordion performing the feasibility and development
     services under the Project, MIP shall pay Nordion in accordance with the
     fees set out in Schedule B, within thirty (30) days of receipt of an
     invoice from Nordion. Such invoice shall, unless otherwise agreed, be
     payable in United States currency. Nordion acknowledges that MIP has
     previously paid to Nordion ** which amount shall be credited
     towards the portion of the facility establishment fee due from MIP to
     Nordion upon execution of this Agreement.

5.   LICENSE

     MIP hereby grants to Nordion a non-exclusive, non-transferable,
     royalty-free license for the term of this Agreement only to use the MIP
     Background Technology that is related to radiolabeling MIBG with I-131 for
     the limited purpose of assisting Nordion in carrying out its obligations
     set out in this Agreement.

* confidential treatment requested *

<PAGE>

                                       4

     MIP represents, warrants and covenants that (i) it is the owner or licensee
     of the MIP Background Technology, (ii) the MIP Background Technology does
     not, to MIP's best information and belief, infringe any patents, copyright
     or other industrial or intellectual property rights of third parties, (iii)
     it has the right to provide the license and right to permit Nordion to use
     the MIP Background Technology to carry out the Project as contemplated
     herein, and (iv) it has not received any written notice of a claim or
     infringement of any patent with respect to such MIP Background Technology.

     MIP shall defend, indemnify and hold Nordion harmless, from and against,
     any allegations, claims, actions or damages arising from claims of
     infringement or misappropriation of a third party's copyright, patents,
     technology or other intellectual property rights resulting from Nordion's
     use of the MIP Background Technology, or any of it, as provided to Nordion
     by MIP hereunder. This indemnity shall survive termination or expiration of
     this Agreement.

6.   OWNERSHIP OF TECHNOLOGY

     (a)  "Nordion Background Technology" shall mean all Nordion proprietary
          technology, including patents, know-how, techniques, methods,
          processes and trade secrets which Nordion owns or uses in performing
          under this Agreement, or which is licensed to Nordion and which is in
          existence in the form of a writing, prototype or can otherwise be
          demonstrated to be the property of Nordion, including but not limited
          to (i) radiopharmaceutical process development and know-how, (ii)
          radiolabeling technologies including but not limited to linkers,
          radiocoating and radioiodination, (iii) radiochemical processing, (iv)
          radioactive containment systems design, (v) radiopharmaceutical
          engineering designs, (vi) radioactive handling, and experimentation,
          (vii) radioactive QC method development such as IRF, ITLC and HPLC,
          (viii) radioprotectants, (ix) radioactive package engineering, and (x)
          radiopharmaceutical aseptic filling and packaging.

<PAGE>

                                       5

          "MIP Background Technology" shall mean all MIP proprietary technology,
          including patents, know-how, techniques, methods, processes and trade
          secrets which MIP owns or uses in performing under this Agreement, or
          which is licensed to MIP and which is in existence in the form of a
          writing, prototype or can otherwise be demonstrated to be the property
          of MIP.

     (b)  All right, title and interest in and to the Nordion Background
          Technology shall remain the property of Nordion. All right, title and
          interest in and to the MIP Background Technology shall remain the
          property of MIP. Nordion and MIP agree that any and all ideas,
          improvements, inventions and works of authorship conceived, written,
          created or first reduced to practice solely by Nordion in the
          performance of this Agreement, except to the extent that it relates to
          Nordion Background Technology or improvements to Nordion Background
          Technology (in which case it shall be owned by Nordion), shall be the
          sole and exclusive property of MIP. Nordion hereby assigns (except to
          the extent owned by to Nordion pursuant to this clause (b) or licensed
          to Nordion by a third party) to MIP all right, title and interest in
          and to any and all such ideas, improvements, inventions and works of
          authorship.

     (c)  Nordion and MIP agree that any and all ideas, improvements, inventions
          and works of authorship conceived, written, created or first reduced
          to practice jointly by Nordion and MIP in the performance of this
          Agreement shall be owned jointly by MIP and Nordion and each of
          Nordion and MIP shall have the right to exploit, for any purpose they
          determine in their sole discretion, such jointly owned property
          without restriction and without any further compensation due to the
          other party.

     (d)  Except as expressly set out herein nothing in this agreement transfers
          or licenses any right, title or interest to MIP Background Technology
          or Nordion Background Technology

<PAGE>

                                       6

     This section shall survive the termination of this agreement for any reason
     including termination or expiration of term, and completion of the Project.

7.   MIP PROPRIETARY INFORMATION

     All data, information, or technology supplied to Nordion by MIP to assist
     Nordion in carrying out its obligations hereunder, shall remain the
     property of MIP and shall be returned by Nordion to MIP upon termination or
     expiration of this Agreement.

8.   DISCLOSURE OF TECHNOLOGY

     It is agreed that disclosure of data, information or technology by Nordion
     or MIP, to the other, during the Project shall not, except to the extent
     granted herein, constitute any grant, option or license under any patent,
     technology or other rights, held by Nordion or MIP, as the case may be.

9.   PROGRAM MANAGERS

     Within thirty (30) days after the execution of this Agreement, the parties
     shall each designate a Program Manager, who shall be responsible for
     coordination and monitoring performance under this Agreement. The Program
     Managers shall meet at least monthly (or more frequently as either party
     might reasonably request), at locations to be agreed or by telephone for
     the purpose of reviewing the status of the project and to assess progress
     against the milestones and activities set forth in Schedule A. Nordion will
     provide reasonable detailed written reports to MIP on a monthly basis
     setting out the progress against milestones as set out in Schedule A. In
     addition, at the end of each of the Phases described in Schedule A, a stage
     gate meeting will take place and a report will be issued and approved by
     both parties, such approval not to be unreasonably withheld.

10.  CONFIDENTIALITY

<PAGE>

                                       7

     During the term of this Agreement and for a period of ten (10) years
     thereafter, Nordion and MIP shall respectively maintain in confidence, and
     not disclose to others for any purpose, other than to its employees or
     agents (which agents shall enter into confidentiality agreements
     incorporating similar terms as set forth herein or be otherwise reasonably
     acceptable to the other party) with a need to know such information to
     perform such party's obligations hereunder, all non-public proprietary or
     confidential information disclosed to such party by the other party,
     whether disclosed orally, in writing or via other media or tangible form,
     including but not limited to the Nordion Background Technology, MIP
     Background Technology and respective improvements thereto, process design,
     formulas, material samples, drawings, reports, regulatory information,
     business information and proposals, forecasts, business strategies,
     financial information and marketing plans ("Confidential Information").
     This obligation of confidentiality shall not apply to the extent that it
     can be established by the party in receipt of such information, that the
     Confidential Information:

     i)   was already known to the receiving party at the time of disclosure;

     ii)  was generally available to the public or otherwise part of the public
          domain at the time of its disclosure;

     iii) became generally available to the public or otherwise part of the
          public domain after its disclosure to the receiving party through no
          act or omission of the receiving party;

     iv)  was disclosed to the receiving party by a third party who was not
          known to the receiving party to have obligations restricting
          disclosure of such information; or

     v)   was independently developed by the receiving party without any use of
          Confidential Information of the disclosing party.

<PAGE>

                                       8

     Each party agrees that it will take the same steps to protect the
     confidentiality to the other party's Confidential Information as it takes
     to protect its own proprietary and confidential information, which shall in
     no event be less than commercially reasonable steps. Each party, and its
     employees and agents, shall protect and keep confidential and shall not
     use, publish or otherwise disclose to any third party, except as permitted
     by this Agreement or with the other party's written consent, the other
     party's Confidential Information. Notwithstanding the forgoing, the
     receiving party may disclose the Confidential Information if compelled to
     do so by judicial process or order of a court or tribunal of competent
     jurisdiction, provided however that in such case the receiving party shall
     as soon as is reasonably possible upon receiving notice that disclosure is
     or may be required, give written notice by facsimile and overnight courier
     to the other party, so that such other party may seek a protective order or
     other remedy from such court or tribunal.

     This section 10 shall survive termination or expiration of this Agreement,
     and completion of the Project in accordance with its terms.

     Notwithstanding the foregoing, Nordion acknowledges and agrees that, as and
     to the extent required pursuant to applicable laws, rules or regulations,
     MIP or Nordion may disclose this Agreement to this U.S. Securities and
     Exchange Commission or Canadian Exchange Commission, the FDA and any other
     applicable regulatory authority or agency. MIP or Nordion, as the case may
     be, agrees to request confidential treatment of the financial provisions,
     and any other provisions it deems reasonably appropriate for confidential
     treatment, where available from such regulatory authority or agency.

11.  INDEMNITY

     Nordion and MIP, as the case may be, shall defend, indemnify and hold
     harmless the other from and against any and all costs, claims, judgments or

<PAGE>

                                       9

     other expenses, (including reasonable attorney fees), arising as a result
     of damages claimed by third parties, in tort, contract or other legal
     theory, occasioned by Nordion's or MIP's negligence or that of their
     respective employees or agents, in carrying out their obligations
     hereunder. This section shall survive termination or completion of this
     Agreement.

     A party (the "Indemnitee") intending to claim indemnification under this
     Agreement shall promptly notify the other party (the "Indemnitor") in
     writing of any action, claim or other matter in respect of which the
     Indemnitee or any of its directors, officers, employees or agents intend to
     claim such indemnification; provided, however, the failure to provide such
     notice within a reasonable period of time shall not relieve the Indemnitor
     of any of its obligations hereunder except to the extent the Indemnitor is
     materially prejudiced by such failure. The Indemnitor shall be entitled to
     control the defense of and/or settle any such action, claim or other
     matter. The Indemnitee agrees to the complete control of such defense or
     settlement by the Indemnitor; provided, however any settlement of such
     claims shall require the Indemnitee's prior written consent unless such
     settlement includes a full release of the Indemnitee, in which case no
     consent shall be required. The Indemnitee and its directors, officers,
     employees and agents shall co-operate fully with the Indemnitor and its
     legal representatives in the investigation and defense of any action, claim
     or other matter covered by this indemnification. The Indemnitee shall have
     the right, but not the obligations, to be represented by counsel of its own
     selection and at its own expense.

12.  NOTICE

     Any notice to be sent to a party hereunder shall be forwarded to:

     Nordion at: 447 March Road
                 Kanata, Ontario, Canada
                 K2K 1X8

<PAGE>

                                       10

     Attention:  Associate General Counsel
                 cc: Program Manager

     MIP at:     160 Second Street,
                 Cambridge Massachusetts,
                 02142, USA

     Attention:  Chief Operating Officer

     Any notice required or authorized to be given by a party to the other in
     accordance with the provisions of this Agreement shall, unless otherwise
     specifically stipulated, be in writing and delivered personally, by
     telegram or electronic facsimile and confirmed by registered mail.

13.  ASSIGNMENT

     Neither Nordion nor MIP shall assign any portion of this Agreement without
     the written consent of the other party, which consent shall not be
     unreasonably withheld. Nordion shall be entitled to subcontract to third
     parties any of its obligations set out in this Agreement in order to carry
     out the Project; provided, however, that Nordion may not subcontract any
     portion of this Agreement unless such subcontractor shall agree to be bound
     by the provisions hereof pertaining to ownership of work performed and
     confidentiality. Notwithstanding the foregoing, a party may assign this
     Agreement and all of its rights and obligations hereunder to any affiliate
     or to any third party in connection with the transfer or sale of all or
     substantially all of its business to which it relates, or to which it may
     transfer all or substantially all of its assets, or in the event of its
     merger, consolidation, change in control or similar transaction, without
     obtaining the prior consent of the other party.

14.  COMPLIANCE

<PAGE>

                                       11

     The Project shall be carried out in compliance with all applicable laws,
     by-laws, rules, regulations and orders of federal, provincial or municipal
     governments or manifestations thereof.

15.  NON WAIVER

     Failure by either party to enforce at any time any of the provisions of
     this Agreement shall not be construed as a waiver of its rights hereunder.
     Any waiver of a breach of any provision hereof shall not affect either
     party's rights in the event of any additional breach.

16.  FORCE MAJEURE

     Neither party hereto shall incur any liability to the other in the event
     that it is prevented or delayed in the performance of its obligations
     hereunder solely by an event of force majeure. For the purpose of this
     Agreement "an event force majeure" shall mean any cause of delay beyond the
     reasonable control of the party liable to perform unless conclusive
     evidence to the contrary is provided and shall include, but not by way of
     limitation, acts of God, flood, power failure, fire, explosion, accident,
     war, revolution, riot, civil, commotion, acts of public enemies, blockage,
     embargo, failure, inability or incapacity of suppliers to have available
     for supply sufficient raw materials, equipment or machinery, interruption
     or delay in transportation, strikes, lockouts, riots, sabotage or other
     labor disruption. The party subject of the event of force majeure shall
     exert commercially reasonable efforts to eliminate, overcome or cure such
     event and to resume performance of its obligations.

17.  PUBLICITY

     The parties agree that, except as set forth in this Agreement and as may
     otherwise be required pursuant to applicable laws, rules, regulations or
     orders, no information concerning this Agreement and the transactions
     contemplated herein shall be made public by either party without the prior
     written consent of the other party, which consent shall not be unreasonably
     withheld or delayed. In

<PAGE>

                                       12

     the event either party decides to issue a press release announcing the
     execution of this Agreement, it shall not do so without the prior written
     consent of the other party, which consent shall not be unreasonably
     withheld or delayed. A copy of any proposed press release shall be provided
     to the other party at least ten (10) business days prior to any proposed
     release.

18.  APPLICABLE LAW

     This Agreement shall be governed and construed in accordance with the laws
     of the Province of Ontario, Canada, without reference to its conflicts of
     laws. The venue for any legal proceeding arising out of this Agreement
     shall be in the Province of Ontario, Canada

<PAGE>

                                       13

     IN WITNESS WHEREOF the parties hereto have executed this Agreement as of
the date first hereinabove written.

                                        MDS NORDION, a division of MDS (Canada)
                                        Inc.

                                        By: /s/ Chris Wagner
                                            ------------------------------------

                                        Molecular Insight Pharmaceuticals, Inc.

                                        By: /s/ John E. McCray
                                            ------------------------------------
<PAGE>

                                       14

                                   SCHEDULE A

   Project Description (Scope of Work), Work Schedule and Project Deliverables

                                  SCOPE OF WORK

This Schedule will serve as the Scope of Work for the tasks related to the
development of the I-131 MIBG process and dose configuration in order to
establish the feasibility of;

          a.   a 5 curie batch size

          b.   a terminally sterilized radiotherapeutic product configuration

          c.   an up to 15 mL fill volume in order to use of an existing Nordion
               packaging

          d.   freezing of final product to enhance stability, provided that the
               formulation and vial are suitable for freezing.

          e.   a suitable radioprotectant to achieve a 5 day shelf life from the
               day of production

          f.   a maximum dose activity of 200 mCl at three (3) days after the
               day of manufacture.

          g.   a free Iodine specification will be less than or equal to 5% at
               expiration.

The project will require the establishment of a facility and four distinct
phases as described below

FACILITY ESTABLISHMENT:

This phase Includes the set up of a development facility in two cells. Cells 41
and 42 will be secured for this development work. These cells are equipped with
Iodine ventilation systems and are heavily shielded permitting full scale (up to
5Ci) I-131 MIBG testing. These cells will also physically accommodate an
autoclave. The cells will be wired to accommodate the required process
equipment. This facility will not be capable of producing GMP sterile or low
endotoxin product.

PHASE I SET UP PROCESS AND ESTABLISH BASELINE

<PAGE>

                                       15

MIP will communicate Ultratrace I-131 MIBG technology from MIP to Nordion
including single dose formulation and assay development work, development test
results and complete assay validations.

MIP is required to provide sufficient Ultratrace(TM) precursor and reference
standard for each phase of the development. The technology transfer will require
meetings between the MIP and Nordion and may require site visits by MIP's
technical experts. All meetings, and any materials used in or generated as a
result of such meetings, and all information discussed in such meetings, are
deemed Confidential Information pursuant to the Agreement.

Perform several dose formulations in accordance with the reaction conditions
prescribed in the MIP procedure and verify QC methods.

Conduct stability testing up to ** using material from the MIP formulation.
It is expected that a new ITLC method will need to be established.

Nordion will prepare and deliver to MIP a written report (the "Phase I Stage
Gate Report") upon completion of Baseline Runs and Assay Verification, which
report shall set forth the completion of Phase I and the associated milestone
payment. Nordion and MIP agree to have a meeting at the end of Phase I to review
and finalize the Phase I Stage Gate Report.

PHASE 2 131 -I MIBG STABILITY OPTIMIZATION BASED ON A 15 ML DISPENSE VOLUME

Nordion to carry out feasibility and optimization experiments to determine the
optimal dose formulation and batch process conditions.

Optimization of product stability in final dose form will be performed using
Tellurium derived I-131 to expedite development.

Using the established stability indicating assays, determine the best
configuration by testing 3 different radioprotectants at 3 different
concentrations with 3 different activity concentrations. This work would be done
with triplicate reactions and duplicate samples.

Each formulation will be tested for stability out to ** at room temperature,
40 degrees and negative 70 degrees per ICH guidelines.

As part of this phase, Nordion will perform a minimal vial breakage study to
determine if the formulation and vial are suitable for freezing.

* confidential treatment requested *

<PAGE>

                                       16

Nordion will prepare and deliver to MIP a written report (the "Phase 2 Stage
Gate Report") upon completion of the Optimization Stability 15 mL Fill Study,
which report shall set forth the completion of Phase II and the associated
milestone payment. Nordion and MIP agree to have a meeting at the end of Phase
II to review and finalize the Phase 2 Stage Gate Report.

PHASE 3 ACTIVITY CONCENTRATION OPTIMIZATION STABILITY (AT 25 ML IF REQUIRED).

Note: This work is not part of this Project but is estimated to take **. It has
not been priced out at this time and this new dose size would require a new
transportation container.

Further refinement of the activity concentration may be required to optimize the
total activity per dose if requested by the customer. This work would utilize
the best radioprotectant configuration determined in the initial optimization
and may require the use of a larger vial size to achieve the minimum acceptable
dose activity and the required product stability.

Experiments would be done at 3 or more different activity concentrations with
triplicate reactions, duplicate samples and stability testing at 3 time points.

PHASE 4 PROCESS CONFIRMATION

Scale up to a 5 curie batch size using Fission derived I-131 while simulating
production conditions for timing of activities.

Produce three (3) full scale 5Ci I-131 MIBG process runs to verify process
capability and product stability. Create and provide master batch record and
summary reports. Perform testing for stability out to ** at room temperature,
40 degrees and negative 70 degrees per ICH guidelines. This is not to be
considered a GMP process validation.

Complete full batch dispensing and QC testing. Use full activity doses to
determine the products stability past shelf life to expiry.

Complete an examination of all product vials post freezing and test Inactive
mock product freezing to determine if there are any major Issues with product
freezing such as vial breakage.

Prepare written project completion report which shall set forth final payment
and be delivered by Nordion to MIP within five days of completion of the "Full
Activity Confirmation Runs" and "Vial Breakage Study".

The duration of the Project is estimated to be ** from the Effective Date.

* confidential treatment requested *

<PAGE>

                                       17

                                      NOTES

1.   It is assumed that the current technology as developed by MIP can be
     replicated and the supplied assays are fully developed or validated. If
     assays require further development, the project price and schedule could be
     impacted.

2.   Further dose size optimization: If the 15 mL fill volume is not achievable,
     subsequent experiments can be conducted at a 25 mL fill in a 50 ml vial.
     This would require a new transport package and would require further
     development. The cost of a new transport package is not part of this
     project.

3.   Tellurium derived I-131 will be used for optimization studies and Fission
     derived I-131 will be used for the final full activity confirmation runs.

4.   A stage gate methodology has been assumed and a ** period has been
     allocated between stages for facility recovery and customer interactions.
     Delays in decision making, at stage gates, beyond ** could result in an
     overall project delay. Findings from each stage gate could result in a
     reevaluation of the Project scope and budget. Minutes from the meeting will
     be signed off by both parties and Issued as a report.

5.   This estimate covers the development of the product and process but does
     not cover the cost of formal validation in accordance with GMP's. These
     requirements would be provided for in a separate estimate and would be
     conducted In the final clinical GMP facility.

6.   Use of the radioprotectant PVP is under license to Nordion and Nordion has
     the right to use such radioprotectant PVP pursuant to this Agreement
     without any encumbrances upon MIP or Its Ultratrace MIBG product. MIP will
     not be obligated to pay any royalties to any third party in connection with
     Nordion's use of radioprotectant PVP.

7.   No binding assay has been developed by MIP and further development of a
     binding assay by Nordion would require additional development and increase
     the estimated cost and duration of the project and is not part of the scope
     of the Project

* confidential treatment requested *

<PAGE>

                                       18

                                  WORK SCHEDULE

The project is anticipated to take ** depending on the need to continue testing
at a 25 mL volume. The following Gantt details the longest anticipated timeline
with the inclusion of the 25 mL fill.

          (BAR CHART DEPICTING WORK SCHEDULE BY MONTH APPEARS HERE)

* confidential treatment requested *

<PAGE>

                                       19

                                   SCHEDULE B

                            FEES AND PAYMENT SCHEDULE

<TABLE>
<C>                                                                    <C>
1.   Facility Establishment:                                           **
        ** of fee invoiced on Effective Date, of which ** was
        previously paid.
        ** of fee invoiced 30 days after completion of facility
        establishment

2.   Phase 1:                                                          **
        ** of fee invoiced on Effective Date
        ** of fee invoiced on issuance of Phase I Stage Gate Report

3.   Phase 2:                                                          **
        ** of fee invoiced on Effective Date
        ** of fee invoiced on Start of Phase 2
        ** of fee invoiced issuance of Phase 2 Stage Gate Report

4.   Phase 3: TBD (if necessary)

5.   Phase 4:                                                          **
        ** of fee invoiced on Effective Date
        ** of fee invoiced on Start of Phase 4
        ** of fee invoiced issuance of Project Completion Report

           Total:                                                      **
</TABLE>

NOTES: 1. Fees are in United States dollars

2. Facility Establishment Fees are non refundable.

* confidential treatment requested *
<PAGE>

(MDS NORDION LOGO)
SCIENCE ADVANCING HEALTH

July 14, 2006

Wendy Graham-Coco
Director, R&D Operations
Molecular Insight Pharmaceuticals, Inc.
160 Second Street
Cambridge, MA 02142

Re: Phase II B - Optimization of Aseptic Process for I-131 MIBG

Dear Wendy,

Please find below a detailed scope of work for Phase 2B of our I-131 MIBG
development project. Should all the details pertaining to work scope and cost
meet your satisfaction, kindly sign and fax this letter to my attention.

I thank you for your help and cooperation in preparing this scope change.

PHASE II B - OPTIMIZATION OF ASEPTIC PROCESS FOR I-131 MIBG

Goal: To determine an optimal formulation of ascorbic acid and gentisic acid
concentrations, to support expiry and test scale up of iodination reaction.

Experimental Plan

Below is a tabular breakdown of the experiments, purpose and timeframe for Phase
2B. A Phase 2B report will also be drafted following completion of the
experimental work, and a meeting will be scheduled to discuss results and plan
for the next step of the project.

<TABLE>
<CAPTION>
                 EXPERIMENT                              PURPOSE:                      TIME
-------------------------------------------   ------------------------------   -------------------
<S>                                           <C>                              <C>
A. 2Ci run: split to provide                  Justification of concentration         **
   Vial 1. (RT in duplicate): 1.5% Ascorbic   of Ascorbic Acid vs. RCP
      acid/ 1.5% Gentisic acid
   Vial 2. (RT in duplicate): 3% Ascorbic        [ASCORBIC ACID]
      acid/ 1.5% Gentisic acid
   Vial 3. (RT in duplicate): 6% Ascorbic
      acid/ 1.5% Gentisic acid
      (WHEN MADE SHIP 1/2 ML OF VIAL 2 TO
         MIP TO TEST)

DECISION POINT: RESULTS OF EXPERIMENT A DETERMINE THE ASCORBIC ACID CONCENTRATION FOR EXPERIMENT B

B. 2Ci run: split to provide                  Justification of concentration          **
   Vial 1. (RT in duplicate): X% Ascorbic     Gentisic acid
      acid/ 0% Gentisic acid
   Vial 2. (RT in duplicate): X% Ascorbic        [GENTISIC ACID]
      acid/ 3% Gentisic acid

   USE OPTIMAL FORMULATION OF ASCORBIC/ GENTISIC ACID FROM ABOVE EXPERIMENTS A&B & MIP TO DO CELL
                              CULTURE ASSAYS ON OPTIMAL FORMULATION

C. 2Ci run: autoclave optimal formulation     Show again why not autoclave            **
   from above

D. 7Ci run: split to provide                  Test scale up of iodination &           **
   Vial 1. Room Temp, in duplicate: Days      Support Expiry
      0,1, 2, 5 & 7
   Vial 2. -80 'C in duplicate Days 1, 2,
      5 & 7

E. Draft Phase 2B Report & Meeting to                                                 **
   Discuss Results

F. Finalize Phase 2B Report                                                           **
</TABLE>

* confidential treatment requested *
<PAGE>

(MDS NORDION LOGO)
SCIENCE ADVANCING HEALTH

Notes

-    QC Testing for experiments A and B will be performed at **, and at various
     intervals up to ** in order to investigate degradation over time at room
     temperature.

-    Ascorbic acid concentration for Experiment B will depend on results
     obtained in Experiment A.

-    MDSN and MIP agree to review experimental results on a weekly basis and lay
     out the experimental plan for the following week.

-    Only one experiment will be performed at a scale up level. All other
     experiments will require 2 Ci of I-131

-    Product will be stored at room temperature or - 80 degrees C as indicated.

Timeline

As indicated in the table above, phase 2B will require approximately ** to
complete. Should a delay be anticipated, MIP will be notified as soon as
possible with an updated timeline.

Price

In accordance with section 3 of the March 22, 2006 Agreement between Molecular
Insight Pharmaceuticals and MDS Nordion, work will be performed at the rate of
US **.

-    A maximum of 4 full time employees may be assigned for the completion of
     the experimental portion. This will result in a maximum of 160 hours/week,
     or ** for the completion of experimental work. In addition documentation
     and reporting fee will apply at the same hourly rate.

-    Please note, MIP will only be charged for actual time incurred for the
     setup and execution of experiments for this project and documentation and
     report costs.

-    The charge rate of I-131 is to be determined and will be documented in a
     separate communication.

-    Materials and purchases will be invoiced at cost.

Should the conditions in this document meet your satisfaction, kindly sign below
and fax a copy to my attention. If you have any questions regarding this plan,
please do not hesitate to contact me.

                                       I here by accept the conditions of
                                       this letter.

Best regards,

                                       Signature/Date: /s/ JOHN W BABICH 7/14/06
                                                       -------------------------
                                       Name: JOHN W BABICH

Mihran Zaroukian                       Molecular Insight Pharmaceuticals
Senior Program Manager
Business Development, Medical Isotopes
MDS Nordion

Cc: Phil Larabie

* confidential treatment requested *
<PAGE>

(MDS NORDION LOGO)

October 11, 2006

Wendy Graham-Coco
Director, R&D Operations
Molecular Insight Pharmaceuticals, Inc.
160 Second Street
Cambridge, MA 02142

RE: AMENDMENT 1 TO THE PROJECT AGREEMENT SIGNED 22 MARCH 2006.

Dear Wendy,

I am pleased to provide you with the following amendment to the I-131 MIBG
feasibility and development agreement between Molecular Insight Pharmaceuticals,
Inc. ("MIP") and MDS Nordion, a division of MDS (Canada) Inc, signed as of 22
March 2006 ("Feasibility Agreement"). The purpose of this amendment is to
evaluate the process developed under this Feasibility Agreement. This work will
be required before beginning process validation. Should all the details
pertaining to the work being carried out meet your satisfaction, kindly sign
both copies and return one to my attention for our records.

PHASE 5 - OPTIMIZATION OF ASEPTIC PROCESS FOR I-131 MIBG

Objective

The scope and objective of this work will be to bridge what has been achieved
under the Feasibility Agreement with respect to the final radiopharmaceutical
process to be carried out under a new facility and clinical trial supply
agreement to be negotiated. As such, several facets of the process need to be
optimized.

Experimental Plan

The following tasks will be added to the Feasibility Agreement and carried out
as part of Phase 5 of the Feasibility Agreement.

     1.   Optimization of reaction apparatus to be used in clinical supply
          facility (Cell 27)

     2.   Investigate the effects of sterile filtration on the product

     3.   Comparison of commercial CBA column versus expanded column

     4.   Bioburden testing of the drug product

     5.   Activity concentration and pH method transfer to radiopharm team

     6.   QC method technology transfer, based on the final formulations*

     7.   Evaluation of QC equipment suitability for all methods

     8.   Transfer knowledge of the entire process from the development team to
          radiopharm team

*    Certain methods to be validated at MIP. See note below.

At the completion of all tasks, a project completion report will be issued
summarizing results.

                                   Page 1 of 4
<PAGE>

(MDS NORDION LOGO)

Timeline

This work will require ** to complete. Should a delay greater than **
be incurred or anticipated by MDS Nordion, MIP will be notified as soon as
reasonably possible with an updated timeline and associated extension of the
term of the Feasibility Agreement pursuant to section 2 thereof.

Price

Section 3 of the Feasibility Agreement stipulated an hourly rate of US **
for any additional work under such agreement. However, this amendment contains a
new phase which will be priced at a fixed fee and the hourly rate will therefore
not apply.

The price for the work outlined for Phase 5 is US **.

The total revised price of the Feasibility Agreement is thus US $**.

Notes:

-    A maximum of three full process runs will be performed as part of the
     verification with the final CBA and sterile filter configurations.

-    Stability tests will not be part of this phase.

-    A maximum of 4 full time employees will be assigned for the completion of
     the experimental portion and any supporting documentation.

-    The timeline and price stipulated above do not include a contingency for
     unexpected work of a material nature. As such, MIP must assume a certain
     degree of risk and Nordion can not be held liable for any unforeseen delays
     in the schedule.

-    Should work outside the scope of the experimental plan be requested by MIP,
     a new letter outlining scope and cost will be provided to capture
     additional work.

-    it is assumed that the HPLC methods for radiochemical identity and purity
     will be developed and validated at MIP and then transferred to Nordion for
     reproducibility. Should considerable development and validation work be
     required by Nordion for these methods, the scope of this amendment will be
     revised.

-    The cost of all materials and equipment is included in this price unless
     stated otherwise.

                                   Page 2 of 4

* confidential treatment requested *
<PAGE>

(MDS NORDION LOGO)

Payment

Payment terms are as follows:

** of total price for Phase 5 ** upon signature of this agreement.

** of total price for Phase 5 ** upon acceptance by MIP of an
amended project completion report.

Should the conditions in this document meet your satisfaction, kindly sign
below. If you have any questions regarding this plan, please do not hesitate to
contact me.

This amendment shall be effective as of the date of signing by MIP.

All other terms and conditions of the Feasibility Agreement shall continue to
apply.

MDS Nordion, a division of MDS
(Canada) Inc.

by: /s/ Illegible
    ---------------------------------

Molecular Insight Pharmaceuticals,
Inc.
hereby agrees this 17th day of
OCTOBER, 2006.

By: /s/ John W. Babich
    ---------------------------------
70625

                                   Page 3 of 4

* confidential treatment requested *
<PAGE>

(MDS NORDION LOGO)

                           Schedule A: Phase 5 Summary

Work in Phase 5 is being undertaken by several groups at MDS Nordion notably,
Process and Product Development (Development), Quality Control (QC),
Microbiology (Micro) and Engineering. The plan is composed of three main
sections. Below is a breakdown with estimated durations for each section.

A)   Process Development **

     a.   CBA column finalization: commercial versus expanded column
          (Development)

     b.   Filtration testing: effect of filtration on the product (Development).

     c.   Conversion of current experimental apparatus into clinical supply
          facility cell 27 (Engineering).

B)   Quality Control **

This work is done in parallel with Process Development, the products produced in
development will be used to supply testing material for the QC methods being
tested. As such, additional process runs may be scheduled, even after section A
is completed in order to supply Azedra for QC method testing. Note these are not
validations of these methods. The HPLC methods being tested are assumed
validated at MIP, and this timeline is estimated with no major modifications to
the method. The Bioburden method requires a final configuration and choice of
CBA and filter, which should be completed in section A.

     a.   HPLC method for Radiochemical purity, identity (Development/QC).

     b.   HPLC method for concentration of excipients (Development/QC).

     c.   Bioburden testing of intermediate drug product (Micro/Development).

     d.   All other QC tests (pH, activity etc), (Development).

     e.   Transition over all methods to QC team (Development, QC, Micro).

C)   Process confirmation **

Once all parameters have been finalized, 3 confirmatory runs will be performed
to ensure robustness of the process and testing methods.

The overall project is estimated at **, which is primarily dependant on the
successful transfer of validated QC methods, and the completion of CBA and
filtration testing.

Estimated Phase 5 plan

<TABLE>
<CAPTION>
                                                Overall Timeline Estimated at 8 Weeks
                                               --------------------------------------
<S>                                            <C>
Process Development
   - CBA column, Filtration                                  **
   - Apparatus for cell 27 including                         **
     - Designing prototype
     - Commissioning
   - Supply material for QC methods                          **
-------------------------------------------------------------------------------------
QC Methods
   - HPLC method testing                                     **
   - Bioburden testing                                       **
   - Other QC methods                                        **
-------------------------------------------------------------------------------------
Process Run
   - Process Runs                                            **
   - Transition to QC                                        **
</TABLE>

                                   Page 4 of 4

* confidential treatment requested *

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}]]